[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 184
1. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR: Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma. Gynecol Oncol; 2009 Dec;115(3):339-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma.
  • OBJECTIVE.: To identify patient characteristics which predict receipt of neoadjuvant chemotherapy (NCT) versus standard therapy (ST) in metastatic ovarian cancer.
  • However, non-Hispanic White (NHW) patients were more as likely to receive ST (P<0.05).
  • Furthermore, medically compromised (MC) patients who were NHW were almost three times more likely to receive ST (OR=2.72, CI=1.02-5.00).
  • The median survival for ST was 55.8 months versus 26 months for NCT (P<0.001).
  • CONCLUSIONS.: Non-clinical factors such as publically funded status and non-Hispanic White race may influence the allocation of NCT for women with metastatic ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / economics


2. Shen X, Wang S, Wang H, Liang M, Xiao L, Wang Z: The role of SDF-1/CXCR4 axis in ovarian cancer metastasis. J Huazhong Univ Sci Technolog Med Sci; 2009 Jun;29(3):363-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of SDF-1/CXCR4 axis in ovarian cancer metastasis.
  • This study was aimed to explore the role of stromal-derived factor 1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) axis in mediating the metastasis of ovarian cancer cells through activation of extracellular signal-regulated kinase-1/2 (ERK-1/2) signaling pathway.
  • A highly metastatic ovarian cancer cell line, SKOV3, was used in the study.
  • Adhesion capability and matrix metalloproteinase (MMP) activity of ovarian cancer cells after exposure to SDF-1alpha were measured by adhesion assay and gelatin zymography.
  • The adhesion of ovarian cancer cells to fibronectin and collagen IV was increased after SDF-1alpha treatment.
  • It was concluded that the SDF-1/CXCR4 axis played a critical role in the metastasis of human ovarian cancer by increasing the adhesion capability of cancer cells and the activity of MMP-2 and MMP-9 via ERK1/2 signaling pathway.
  • [MeSH-major] Chemokine CXCL12 / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Receptors, CXCR4 / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Jan 27;124(2):407-21 [16439213.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):26767-74 [17631494.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):171-9 [15246052.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):226-33 [16631235.001]
  • [Cites] Science. 2004 Aug 13;305(5686):1000-3 [15310902.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):772-8 [12548574.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):233-45 [15339043.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4961-5 [11431324.001]
  • [Cites] J Clin Invest. 1999 Nov;104(9):1199-211 [10545519.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5930-8 [12384559.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Bone Miner Res. 2003 Aug;18(8):1404-18 [12929930.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):595-9 [9634238.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):117-30 [16125170.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):241-53 [15921680.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8420-7 [15548713.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):289-302 [14567988.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):181-5 [15246053.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):465-72 [15695388.001]
  • (PMID = 19513623.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


3. Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P: Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:299-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.
  • Sternal and costal metastases from ovarian cancer are extremely rare.
  • We present here a case of a 47-year-old woman with thoracic wall metastasis from serous-papillary ovarian carcinoma that occurred 3 years after the initial diagnosis, although the patient had received various regimens of intense platinum-based chemotherapy.
  • We also discuss the possible mechanisms through which the biologic and metastatic behavior of this tumor is expressed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515608.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 10
  •  go-up   go-down


Advertisement
4. Wu XF, Chen Y: [Management and prognosis of metastatic ovarian carcinoma from nongenital tract]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jun;40(6):404-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management and prognosis of metastatic ovarian carcinoma from nongenital tract].
  • OBJECTIVE: To study the management and prognosis of nongenital metastatic ovarian carcinoma.
  • METHODS: Thirty-four patients with nongenital metastatic ovarian carcinoma who were admitted in to Zhongnan Hospital of Wuhan University between 1998 and 2004 were analyzed retrospectively.
  • CONCLUSIONS: Most of nongenital metastatic ovarian carcinomas come from tumors of stomach and intestine.
  • Optimal cytoreductive surgery and chemotherapy play an important role in the management and prognosis of nongenital metastatic ovarian carcinoma.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008893.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


5. Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown JV 3rd: Ovarian cancer metastatic to the breast. Gynecol Oncol; 2006 Aug;102(2):386-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the breast.
  • BACKGROUND: Metastatic ovarian cancer to the breast should be considered in the differential diagnosis for gynecologic cancer patients with a breast tumor.
  • CASES: We present three ovarian cancer patients who developed metastatic ovarian cancer to the breast.
  • All patients were heavily pre-treated prior to the development of metastatic disease.
  • Currently, one patient is alive at 64 months following initial detection of her metastatic disease to the breast.
  • The second and third patients are also alive for 30 and 3 months subsequent to their diagnosis of metastatic disease.
  • CONCLUSION: Although metastatic ovarian cancer to the breast following treatment for ovarian cancer is rare and associated with a poor prognosis, oncology physicians should be prepared to contend with disease metastatic to the breast.
  • [MeSH-major] Breast Neoplasms / secondary. Ovarian Neoplasms / pathology


6. Jiang R, Tang J, Cheng X, Zang RY: Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol; 2009 Jan;35(1):92-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: We sought to investigate survival impacts of metastasectomy in women with Krukenberg tumors of the ovary and survival benefits in different origins (gastric cancer, colorectal cancer, or others).
  • METHODS: All patients diagnosed with Krukenberg tumors of the ovary who underwent surgical treatment at a single institution between 1997 and 2003 were retrospectively evaluated.
  • RESULTS: A total of 54 patients with Krukenberg tumors of the ovary were identified.
  • There was a significant difference in survival between patients with metastatic disease confined to the ovaries and those with extensive metastases, with an estimated median survival of 30.7 months and 10 months, respectively (P=0.02).
  • Multivariate analysis suggested that the origin of ovarian metastatic carcinoma (P<0.01), residual disease after metastasectomy (P<0.01), and KPS (Karnofsky performance status) (P=0.03) were independent prognostic factors of survival.
  • CONCLUSIONS: Patients with Krukenberg tumors from colorectal cancer experience a better prognosis than those from gastric cancer and benefit more from metastasectomy.
  • And metastasectomy significantly lengthens overall survival in patients with primary colorectal or breast cancer, higher KPS score, and those with optimal metastasectomy.
  • [MeSH-major] Krukenberg Tumor / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632244.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Tsubono M, Kaneko I, Kii E, Tanaka T, Murata T, Kamimura K, Deguchi Y, Nonogaki H, Yasumizu R: [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. Gan To Kagaku Ryoho; 2005 Mar;32(3):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
  • A 46-year-old woman who had received mastectomy for breast cancer 6 years earlier complained of abdominal distension.
  • Computed tomography and ultrasonography revealed massive ascites and ovarian swelling of both sides.
  • She was diagnosed as having primary ovarian cancer and peritoneal dissemination, and underwent a total hysterectomy as well as ovarectomy on both sides.
  • After surgery, she received a sequential chemotherapy, ie, intraabdominal injection of carboplatin (CBDCA 300 mg/m2) and div administration of paclitaxel (PTX 180 mg/m2) as a standard regimen for advanced ovarian cancer.
  • However, detailed histological examinations showed that the ovarian cancer had metastasized from her breast cancer.
  • It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted.
  • Therefore, no standard therapy has been established for breast cancer metastasizing to the ovarium.
  • No evidence of recurrence of breast cancer has been noted 1 year after surgery.
  • This result suggests that weekly administration of PTX and intraabdominal injection of CBDCA might be beneficial in the treatment of recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy


8. Ohta S, Yamakawa Y, Hasegawa T, Tateno M, Matsui K: [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report]. Gan To Kagaku Ryoho; 2007 Jan;34(1):117-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced ovarian cancer with Sister Mary Joseph's nodule--a case report].
  • A metastatic umbilical tumor,which we call Sister Mary Joseph's nodule (SMJN), is a sign of poor prognosis despite the primary site of malignant tumor.
  • We describe here a patient with an advanced ovarian cancer and SMJN.
  • As a result of systemic examination, the patient was diagnosed as stage IV ovarian cancer and rapidly underwent an optimal operation.
  • Postoperatively, the chemotherapy for advanced ovarian tumors was begun (paclitaxel 180 mg/m(2) and carboplatin AUC 5, 10 courses every 3 weeks).
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Umbilicus

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220685.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD: Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol; 2007 Mar;196(3):245.e1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
  • OBJECTIVE: The purpose of this study was to identify genes that are highly differentially expressed in metastatic serous papillary ovarian tumors (MET) when compared with primary ovarian serous carcinomas (OSPC).
  • STUDY DESIGN: An oligonucleotide microarray with probe sets complementary to >14,500 human genes was used to determine whether patterns of gene expression may differentiate OSPC from MET in 31 snap-frozen serous papillary ovarian carcinomas (ie, 14 primary OSPC and 17 omental metastasis [MET]).
  • CONCLUSION: Gene expression profiling may differentiate metastatic ovarian cancer from primary OSPC.
  • The identification of metastasis-associated genes may provide a foundation for the development of new type-specific diagnostic strategies and treatment for metastatic ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. Gene Expression Profiling. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2007 Nov;197(5):555; author reply 555-6 [17980211.001]
  • (PMID = 17346539.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Nojkov B, Cappell MS: Safety and efficacy of ERCP after recent myocardial infarction or unstable angina. Gastrointest Endosc; 2010 Oct;72(4):870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven patients subsequently did well (mean hospital discharge 6.5 days after ERCP); 1 patient with metastatic ovarian cancer remained ventilator dependent, and another patient with multiple comorbidities had a fatal pulmonary embolus 10 days after ERCP.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20883868.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


11. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res; 2006 Jun;32(3):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
  • AIM: New biomarkers other than carbohydrate antigen (CA) 125 are needed for the detection of ovarian cancer.
  • We evaluated the preoperative plasma OPN level as a diagnostic biomarker for ovarian cancer in comparison with CA125.
  • METHODS: Preoperative plasma OPN and CA125 levels were measured and compared in 32 patients with ovarian cancer, 34 patients with benign ovarian tumor, 30 patients with other gynecologic cancers and 31 healthy women.
  • Preoperative plasma OPN levels were also assessed according to tumor stage, the volume of ascites and histological types.
  • The sensitivity and specificity for predicting ovarian cancer was compared between OPN and CA125.
  • RESULTS: Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women.
  • Stage IV ovarian cancer patients and ovarian cancer patients with ascites had higher plasma OPN levels than those without ascites and in a lower stage.
  • The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125.
  • CONCLUSION: Preoperative OPN is a useful biomarker for predicting ovarian cancer.
  • Larger studies of patients with ovarian cancer showing a low CA125 level or in early stages of ovarian cancer are needed.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / blood. Sialoglycoproteins / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764622.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


12. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report).
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • Herein, we describe an unusual case of ovarian mucinous cystadenocarcinoma that metastasized to the mandibular gingiva as an initial manifestation.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • A positron emission tomography and computed tomography using 18F-fluorodeoxyglucose depicted an ovarian tumor with multiple pelvic and paraaortic lymph node swellings.
  • A magnetic resonance imaging (MRI) clearly demonstrated the presence of an ovarian cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT: Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Res Treat; 2010 Oct;123(3):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
  • Sagopilone is a novel, fully synthetic epothilone that has shown promising preclinical activity in a range of tumor models, including platinum-resistant ovarian cancer and metastatic breast cancer (MBC).

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697802.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00313248
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzothiazoles; 0 / Epothilones; 0 / sagopilone
  •  go-up   go-down


14. Le T, Faught W, Hopkins L, Fung-Kee-Fung M: Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer? J Obstet Gynaecol Can; 2009 Jan;31(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?
  • OBJECTIVES: To examine the impact of delayed primary interval surgical debulking in women with ovarian cancer who show resistance to neoadjuvant platinum-based chemotherapy.
  • METHODS: We carried out retrospective chart reviews to identify women treated for ovarian cancer between 1997 and 2005 who were resistant to neoadjuvant platinum-based chemotherapy based on CA-125 criteria.
  • CONCLUSION: In women with ovarian cancer who have demonstrated platinum resistance after primary neoadjuvant chemotherapy, optimal tumour debulking can further improve response to subsequent platinum-based chemotherapy and prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery


15. Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, Cragun JM, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A: Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1733-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes associated with ovarian cancer metastasis using microarray expression analysis.
  • Although the transition from early- to advanced-stage ovarian cancer is a critical determinant of survival, little is known about the molecular underpinnings of ovarian metastasis.
  • We hypothesize that microarray analysis of global gene expression patterns in primary ovarian cancer and metastatic omental implants can identify genes that underlie the metastatic process in epithelial ovarian cancer.
  • We utilized Affymetrix U95Av2 microarrays to characterize the molecular alterations that underlie omental metastasis from 47 epithelial ovarian cancer samples collected from multiple sites in 20 patients undergoing primary surgical cytoreduction for advanced-stage (IIIC/IV) serous ovarian cancer.
  • Fifty-six genes demonstrated differential expression between ovarian and omental samples (P < 0.01), and twenty of these 56 differentially expressed genes have previously been implicated in metastasis, cell motility, or cytoskeletal function.
  • A Bayesian statistical tree analysis was used to identify a 27-gene expression pattern that could accurately predict the site of tumor (ovary versus omentum).
  • We conclude that gene expression patterns that distinguish omental metastasis from primary epithelial ovarian cancer can be identified and that many of the genes have functions that are biologically consistent with a role in oncogenesis, metastasis, and p53 gene networks.
  • [MeSH-major] Genes, Neoplasm. Neoplasm Metastasis / genetics. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Bayes Theorem. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. Omentum / pathology. Ovary / pathology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009964.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Wallace W, Mulholland K, Epanomeritakis E: Bleeding gastric varices--a rare complication of ovarian cancer. Int J Clin Pract; 2005 Jan;59(1):119-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleeding gastric varices--a rare complication of ovarian cancer.
  • Ovarian carcinoma recurring beyond 10 years, following primary treatment with no interval disease, is also a rare occurrence.
  • We report an unusual case of bleeding gastric varices secondary to splenic venous obstruction as a result of metastatic ovarian carcinoma.
  • This occurred 21 years following surgery and adjuvant chemotherapy for primary ovarian carcinoma.
  • To our knowledge, until now, there have been no reported cases of splenic venous hypertension due to ovarian carcinoma.
  • [MeSH-major] Esophageal and Gastric Varices / etiology. Gastrointestinal Hemorrhage / etiology. Hypertension, Portal / etiology. Ovarian Neoplasms / complications


17. Kizer N, Zighelboim I, Rader JS: Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. Int J Gynecol Cancer; 2009 Feb;19(2):237-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer.
  • BACKGROUND: The argon beam coagulation (ABC) is a safe and effective tool for surgical cytoreduction of metastatic ovarian carcinomas.
  • CASE: A 66-year-old woman with newly diagnosed advanced stage epithelial ovarian cancer underwent primary cytoreductive surgery involving ABC of tumor implants.
  • [MeSH-major] Abdominal Neoplasms / surgery. Adenocarcinoma / surgery. Gynecologic Surgical Procedures / adverse effects. Heart Arrest / etiology. Laser Coagulation / adverse effects. Ovarian Neoplasms / surgery


18. Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B: Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer; 2008 Jan 1;112(1):84-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
  • BACKGROUND: Death receptors mediate both apoptosis and survival in cancer cells.
  • The authors analyzed death receptor expression in metastatic ovarian carcinoma.
  • METHODS: Viable tumor cells in ovarian carcinoma effusions (n = 95) were analyzed for DR4, DR5, Fas, TNFR1, and TNFR2 expression using flow cytometry.
  • DR4 (P = .005) and TNFR2 (P = .041) expression was higher in FIGO stage IV compared with stage III tumors.
  • CONCLUSIONS: The authors have presented the first evidence of death receptor coexpression in ovarian carcinoma effusions.
  • The association of death receptor expression in effusions with advanced stage, poor response to chemotherapy, and shorter survival suggests that these molecules are linked to an aggressive clinical course in metastatic ovarian carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Receptors, Death Domain / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17985388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Death Domain
  •  go-up   go-down


19. Van Trappen PO, Cullup T, Troke R, Swann D, Shepherd JH, Jacobs IJ, Gayther SA, Mein CA: Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol; 2007 Jan;104(1):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer.
  • OBJECTIVE: To date, most mtDNA mutations in cancer have been identified in the control region (D-loop) containing the major promoters.
  • However, almost all studies used one sample per tumor and there is no clear evidence whether metastatic deposits harbor different mtDNA variants.
  • To establish whether different mtDNA variants can be found in the same cancer but at different sites, we analyzed a series of unilateral and bilateral primary epithelial ovarian cancers as well as paired metastatic tumor deposits.
  • METHODS: We sequenced the D-loop region in 52 different tumor samples of 35 ovarian cancer cases, as well as matched normal tissues.
  • Seventeen of those 35 cases had bilateral ovarian cancer, with a sample from each tumor analyzed.
  • RESULTS: Eighty-six polymorphisms (4 new in ovarian cancer) were detected, and 9 different somatic mtDNA mutations were found in 26% (9 of 35) of ovarian cancer cases; all were homoplasmic in nature.
  • Six of the mutations were novel in ovarian cancer.
  • In 24% (4 of 17) of cases with bilateral ovarian tumors, different mtDNA variants were found between paired tumors, suggesting the presence of different clonal populations of cancer cells.
  • Metastatic tumor deposits showed identical mtDNA variants to those found in at least one of the ovarian tumors in cases with bilateral ovarian cancer.
  • [MeSH-major] DNA, Mitochondrial / genetics. DNA, Neoplasm / genetics. Mutation. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16942794.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


20. Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B: Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol; 2005 Nov;33(5):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effusions from patients diagnosed with ovarian (=24) and breast (=38) adenocarcinomas and MM (=24) (total = 86) were analyzed for 67-kd LR protein expression, using immunocytochemistry.
  • Protein expression of the 67-kd LR was frequently detected in carcinomas (19/24 ovarian tumors, 79%; 15/38 breast tumors, 39%), but was rare in MM (2/24 cases, 8%), despite the presence of mRNA transcripts for the receptor in all 21 specimens studied using RT-PCR.
  • Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
  • They additionally suggest that the failure of MM to express the 67-kd LR protein, as opposed to the frequent expression in carcinomas with proven metastatic capacity, may be one of the factors contributing to the reduced ability of the former tumor to metastasize to distant organs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Female. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240397.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Laminin
  •  go-up   go-down


21. Kullar P, Stonard C, Jamieson N, Huguet E, Praseedom R, Jah A: Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer. World J Surg Oncol; 2009;7:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic embryonal sarcoma masquerading as metastatic ovarian cancer.
  • CASE PRESENTATION: We report a case of a 52 year old woman having previously undergone treatment for ovarian serous papillary carcinoma who subsequently presented with a large solitary mass in the liver.
  • Initially this was presumed to be metastasis from the ovarian primary however, on further examination it was shown to be a primary hepatic embryonal sarcoma.
  • CONCLUSION: Primary liver tumors should be considered in differential diagnoses in patients with ovarian cancer who subsequently present with liver tumors.
  • This is particularly important when there is no direct evidence of recurrence of ovarian cancer.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Liver Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Sarcoma / pathology


22. Behne MJ, Hauswirth U, Menz A, Brüllke N, Müllerleile U, Moll I: [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy]. Hautarzt; 2008 Nov;59(11):917-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].
  • [Transliterated title] Akrale Nekrosen bei metastasiertem Ovarialkarzinom. Ausdruck eines singulären Moschkowitz-Syndroms unter Gemcitabin-Chemotherapie.
  • In the differential diagnosis, Raynaud's syndrome should be considered as a premonitory paraneoplasia, a risk factor for the occurrence of acral necrosis in patients with a malignant tumour undergoing chemotherapy, particularly patients with ovarian carcinoma receiving gemcitabine treatment.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Fingers / pathology. Hand Dermatoses / chemically induced. Hand Dermatoses / therapy. Ovarian Neoplasms / drug therapy. Purpura, Thrombotic Thrombocytopenic / chemically induced. Purpura, Thrombotic Thrombocytopenic / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2007 Apr;30(2):101-5 [17414457.001]
  • [Cites] Br Med J. 1967 Jul 22;3(5559):208-12 [6028467.001]
  • [Cites] Am J Hematol. 1998 Apr;57(4):293-302 [9544973.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2 Pt 2):S21-3 [12928002.001]
  • [Cites] Thromb Res. 1985 Jun 1;38(5):469-79 [2861671.001]
  • [Cites] Zentralbl Bakteriol B. 1978 Sep;167(3):253-61 [104483.001]
  • [Cites] Arthritis Rheum. 1985 Jan;28(1):87-92 [3871330.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Feb;30(2):332-4 [16565677.001]
  • [Cites] Hautarzt. 2006 Oct;57(10):927-38; quiz 941 [16964476.001]
  • [Cites] Dermatologica. 1990;181(3):202-6 [2135387.001]
  • [Cites] Clin Exp Dermatol. 1996 Sep;21(5):381-2 [9136163.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):808-9 [9469381.001]
  • [Cites] DICP. 1989 Jul-Aug;23(7-8):582-8 [2669373.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):547-53 [16470522.001]
  • [Cites] Cancer. 1999 May 1;85(9):2023-32 [10223245.001]
  • [Cites] Clin Rheumatol. 1993 Jun;12(2):281-2 [8358996.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):553-8 [15612026.001]
  • [Cites] Scand J Clin Lab Invest. 1978 Dec;38(8):761-4 [741205.001]
  • [Cites] Hautarzt. 2006 Sep;57(9):819-28; quiz 829 [16902805.001]
  • [Cites] Hautarzt. 1999 Oct;50(10):748-52 [10550363.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1343-9 [2254771.001]
  • [Cites] Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34 [11702367.001]
  • [Cites] Ann Intern Med. 1984 Dec;101(6):798-9 [6497196.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):267-73 [15975643.001]
  • [Cites] Mayo Clin Proc. 1996 Mar;71(3):253-8 [8594283.001]
  • [Cites] Med Klin (Munich). 2001 Jun 15;96(6):343-50 [11450586.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):772-8 [11380469.001]
  • [Cites] Eur J Dermatol. 2002 May-Jun;12(3):296-300 [11978579.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1530-3 [7932808.001]
  • [Cites] Cancer Treat Rev. 2005;31 Suppl 4:S29-37 [16360545.001]
  • [Cites] Ann Rheum Dis. 1997 Apr;56(4):224-5 [9165993.001]
  • [Cites] Kidney Int. 2006 Jul;70(1):16-23 [16760911.001]
  • [Cites] Arthritis Rheum. 2003 Aug;48(8):2246-55 [12905479.001]
  • [Cites] J Rheumatol. 2005 Nov;32(11):2144-9 [16265692.001]
  • [Cites] Nephrol Dial Transplant. 2006 Nov;21(11):3038-45 [16968717.001]
  • [Cites] Dermatology. 1999;199(2):183-4 [10559594.001]
  • [Cites] Rheum Dis Clin North Am. 1990 Feb;16(1):11-30 [2406802.001]
  • [Cites] J Clin Rheumatol. 2007 Aug;13(4):187-92 [17762451.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1984;74(1):63-6 [6608501.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):728-31 [12860727.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:407-23 [15561695.001]
  • [Cites] J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S73-6 [15280817.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]
  • [Cites] Ann Surg. 1987 Jul;206(1):62-8 [3606232.001]
  • [Cites] Am J Nephrol. 1999;19(5):590-3 [10575189.001]
  • [Cites] Rheum Dis Clin North Am. 2005 Aug;31(3):465-81, vi [16084319.001]
  • [Cites] Int J Colorectal Dis. 1996;11(4):196-7 [8876279.001]
  • (PMID = 18368377.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


23. Burkart CM, Grisel JJ, Hom DB: Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope; 2008 Sep;118(9):1539-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Diagnosis, Differential. Endoscopy. Female. Follow-Up Studies. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Rupture, Spontaneous. Vascular Endothelial Growth Factor A

  • MedlinePlus Health Information. consumer health - Nose Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622319.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


24. Juretzka MM, Horton FR, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Flores RM, Barakat R, Chi DS: Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature. Gynecol Oncol; 2006 Mar;100(3):618-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature.
  • BACKGROUND: Previous studies have reported the results of full-thickness diaphragmatic resection for ovarian cancer metastatic to the diaphragm.
  • Gore and Associates, Inc., Newark, DE) graft.
  • [MeSH-major] Diaphragm / surgery. Ovarian Neoplasms / surgery. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TEFLON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226799.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


25. Takei Y, Mizukami H, Saga Y, Kobayashi H, Suzuki M, Matsushita T, Ozawa K, Suzuki M: Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro. Int J Cancer; 2005 Jan 1;113(1):54-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro.
  • A Kunitz-type protease inhibitor, bikunin, is known to suppress the invasion and metastasis of cancer cells.
  • To increase its affinity for cancer cells, we constructed a chimeric gene, ATF-HI8, and investigated the anti-invasive and anti-migratory activity of ATF-HI8 on ovarian cancer cells.
  • ATF-HI8-expressing plasmid and ATF-expressing plasmid were introduced into the highly invasive and metastatic ovarian cancer cell line HRA.
  • These results indicate that the overexpression of ATF-HI8 inhibits the invasion and migration of ovarian cancer cells without affecting cell proliferation and suggest that HI8 is involved in the anti-invasive and the anti-migratory activities, and the addition of ATF brought about the increase in the anti-migratory activity of HI8.
  • The above findings suggest the applicability of therapeutic strategies targeting the inhibition of peritoneal invasion and dissemination of ovarian cancer by the use of the chimeric gene ATF-HI8.
  • [MeSH-major] Genetic Therapy. Membrane Glycoproteins / genetics. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Recombinant Fusion Proteins / genetics. Trypsin Inhibitor, Kunitz Soybean / genetics. Urokinase-Type Plasminogen Activator / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386422.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; 0 / SPINT2 protein, human; 0 / Serine Proteinase Inhibitors; 9088-41-9 / Trypsin Inhibitor, Kunitz Soybean; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


26. Yuan ZF, Shi HR, Sun HM, Li WC: [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):555-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma].
  • [MeSH-major] Homeodomain Proteins / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary. Trans-Activators / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980105.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


27. Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, Pujade-Lauraine E: Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study.
  • The objective of the study is to determine whether surgery influences the outcome of stage IV ovarian cancer.
  • The study design is as follows: From May 1995 to December 2000, 129 patients with FIGO stage IV ovarian cancer, recruited in 42 centers, were prospectively included in GINECO first-line randomized studies of platinum-based regimens with paclitaxel administered simultaneously or sequentially.
  • In conclusion, this study shows a significant benefit of debulking surgery in stage IV ovarian cancer patients who responded to neoadjuvant chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Epithelial Cells / pathology. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367318.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, Vanpelt H, Flessner MF: Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration. Clin Cancer Res; 2006 Mar 15;12(6):1906-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration.
  • EXPERIMENTAL DESIGN: Human ovarian tumors (SKOV-3 and OVCAR-3) were established in the abdominal wall of athymic rats.
  • CONCLUSIONS: Reduction of collagen, but not hyaluronan, in the matrix of ovarian xenografts enhanced the transport of i.p. injected antibody.
  • [MeSH-major] Collagen / metabolism. Immunoglobulin G / therapeutic use. Immunotherapy / methods. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA085984; United States / NIDDK NIH HHS / DK / DK048479
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunoglobulin G; 9007-34-5 / Collagen; EC 3.2.1.35 / Hyaluronoglucosaminidase; EC 3.4.24.- / Collagenases; P188ANX8CK / Trastuzumab
  •  go-up   go-down


29. Chen CY, Wu YC, Yen MS, Hung JH, Yuan CC, Chao KC: The power Doppler velocity index, pulsatility index, and resistive index can assist in making a differential diagnosis of primary ovarian carcinoma and Krukenberg tumors: a preliminary study. J Ultrasound Med; 2007 Jul;26(7):921-6; quiz 927-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power Doppler velocity index, pulsatility index, and resistive index can assist in making a differential diagnosis of primary ovarian carcinoma and Krukenberg tumors: a preliminary study.
  • OBJECTIVE: The aim of this study was to compare the effectiveness of transvaginal power Doppler sonography with spectral Doppler analysis as an aid in preoperatively distinguishing primary ovarian carcinoma and metastatic carcinoma to the ovary (Krukenberg tumors).
  • METHODS: Fifty women with ovarian disease were preoperatively examined with transvaginal power Doppler sonography.
  • Twelve patients with metastatic carcinoma to the ovary were classified as group 1; 38 patients with primary ovarian carcinoma were classified as group 2.
  • RESULTS: The PI, RI, and VeI were significantly lower in patients with metastatic carcinoma to the ovary than those with primary ovarian carcinoma (P < .05).
  • Low impedance (PI, RI, and VeI) might assist us in making differential diagnoses between primary ovarian carcinoma and Krukenberg tumors according to our preliminary results.
  • [MeSH-major] Carcinoma / ultrasonography. Krukenberg Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography. Pulsatile Flow / physiology. Ultrasonography, Doppler. Vascular Resistance / physiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / physiopathology. Adenocarcinoma, Mucinous / ultrasonography. Adult. Aged. Blood Flow Velocity / physiology. Carcinoma, Endometrioid / physiopathology. Carcinoma, Endometrioid / ultrasonography. Cystadenocarcinoma, Papillary / physiopathology. Cystadenocarcinoma, Papillary / ultrasonography. Cystadenocarcinoma, Serous / physiopathology. Cystadenocarcinoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasms, Germ Cell and Embryonal / physiopathology. Neoplasms, Germ Cell and Embryonal / ultrasonography. Prospective Studies. Regional Blood Flow / physiology. Sex Cord-Gonadal Stromal Tumors / physiopathology. Sex Cord-Gonadal Stromal Tumors / ultrasonography. Ultrasonography, Doppler, Color. Ultrasonography, Doppler, Pulsed


30. Yu K, Reisacher W: Metastatic ovarian cancer to the palate: the first reported case. Otolaryngol Head Neck Surg; 2008 May;138(5):692-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian cancer to the palate: the first reported case.
  • [MeSH-major] Dysgerminoma / secondary. Ovarian Neoplasms / pathology. Palatal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439484.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Testelmans D, Van Raemdonck D, Amant F, De Wever W, Verbeken E, Nackaerts K: Late recurrent ovarian carcinoma metastatic to the thoracic wall. Acta Clin Belg; 2010 Sep-Oct;65(5):354-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrent ovarian carcinoma metastatic to the thoracic wall.
  • Ovarian cancer is the second most common gynaecologic malignancy.
  • Ovarian carcinomas typically metastasize to multiple sites via exfoliation, lymphatic spread or direct invasion.
  • We present a rare case of a very late recurrence of ovarian carcinoma into the thoracic wall, heralded by thoracic pain in a patient otherwise disease-free for 23 years.
  • This unusual and late presentation of an ovarian cancer metastasis underscores the need for continued awareness and attention to new symptoms in patients with ovarian cancer who show prolonged disease-free intervals.
  • [MeSH-major] Ovarian Neoplasms / pathology. Thoracic Neoplasms / secondary. Thoracic Wall

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21128565.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


32. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics; 2005 Apr;4(4):346-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.
  • Cancer can be defined as a deregulation or hyperactivity in the ongoing network of intracellular and extracellular signaling events.
  • Treatment of ovarian epithelial carcinoma almost always takes place in a metastatic setting since unfortunately the disease is often not detected until later stages.
  • Thus, in addition to elucidation of the molecular network within a tumor specimen, critical questions are to what extent do signaling changes occur upon metastasis and are there common pathway elements that arise in the metastatic microenvironment.
  • For individualized combinatorial therapy, ideal therapeutic selection based on proteomic mapping of phosphorylation end points may require evaluation of the patient's metastatic tissue.
  • [MeSH-major] Carcinoma / metabolism. Molecular Biology / methods. Ovarian Neoplasms / metabolism. Protein Array Analysis / methods. Proteomics / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671044.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA64602; United States / NCI NIH HHS / CA / P50CA83639A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides
  • [Number-of-references] 79
  •  go-up   go-down


33. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR: Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle; 2010 Jan 15;9(2):260-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
  • Current therapies for metastatic ovarian carcinoma are based on surgical debulking followed by chemotherapy.
  • After more than three decades implementing treatments that selectively target the tumor cell, the 5-year survival rate for metastatic ovarian cancer patients is still lower than 30%.
  • Recently, leukocytes in the ovarian cancer microenvironment such as regulatory T cells and immature pro-angiogenic/tolerogenic myeloid cells have been demonstrated to play a fundamental role in tumor progression.
  • This review focuses on our recent understanding of the potential of eliminating and/or modulating the phenotype of these leukocytes in vivo and in situ as a novel intervention to complement standard ovarian cancer treatments.
  • The significant effects of targeting these crucial microenvironmental players on cancer vascularization, local tumor growth, distal metastatic spreading and spontaneous anti-tumor immune responses are discussed.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Jan 15;105(2):679-81 [15358628.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):207-8 [15766657.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1182-7 [15785750.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] Am J Reprod Immunol. 2005 Dec;54(6):369-77 [16305662.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):871-81 [16606666.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):635-42 [16627987.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):159-70 [16904613.001]
  • [Cites] Eur J Surg Oncol. 2006 Oct;32(8):875-86 [16704916.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2691-702 [17101732.001]
  • [Cites] Adv Exp Med Biol. 2007;590:185-93 [17191386.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):425; author reply 426 [17210725.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1083-8 [17317815.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):876-83 [17327609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 [17360651.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4783-9 [17510407.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8900-5 [17875732.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Trends Immunol. 2007 Dec;28(12):519-24 [17981504.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):903-7 [18026089.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):825-31 [18064003.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3372-9 [18519766.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):2125-38 [18725522.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7684-91 [18768667.001]
  • [Cites] Cell Cycle. 2008 Aug 15;7(16):2452-5 [18719382.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):2974-7 [18838866.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7667-73 [19047092.001]
  • [Cites] Mol Immunol. 2008 Dec;46(2):258-68 [18824264.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1761-70 [19273160.001]
  • [Cites] Cell Cycle. 2009 Apr 1;8(7):970-6 [19270527.001]
  • [Cites] Expert Opin Biol Ther. 2009 Jun;9(6):677-88 [19456205.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1930-4 [19448397.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1818-9 [19471123.001]
  • [Cites] J Transl Med. 2009;7:49 [19545375.001]
  • [Cites] Blood. 2009 Jul 23;114(4):901-14 [19383967.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6331-8 [19602595.001]
  • [Cites] J Clin Invest. 2009 Aug;119(8):2231-44 [19620771.001]
  • [Cites] Curr Opin Pharmacol. 2009 Aug;9(4):470-81 [19616475.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7329-37 [19738057.001]
  • [Cites] Nature. 2009 Sep 17;461(7262):E4; discussion E5 [19759568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 [19805141.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):181-9 [18176599.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(4):e1983 [18431473.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Annu Rev Immunol. 2000;18:423-49 [10837065.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Clin Lymphoma. 2000 Sep;1(2):110-6; discussion 117 [11707818.001]
  • [Cites] Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31 [11707860.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):113-5 [12086868.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7042-9 [12460925.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):44-51 [12669470.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1860-4 [12702574.001]
  • [Cites] Nat Med. 2003 May;9(5):562-7 [12704383.001]
  • [Cites] Circ Res. 2003 Nov 28;93(11):1034-46 [14645134.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):331-3 [14667498.001]
  • [Cites] J Exp Med. 2004 Mar 15;199(6):775-84 [15007094.001]
  • [Cites] Cancer Treat Res. 2004;118:173-95 [15043193.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):215-6 [15254281.001]
  • [Cites] Cell. 2004 Jul 23;118(2):229-41 [15260992.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Science. 1998 Aug 21;281(5380):1191-3 [9712583.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • (PMID = 20023378.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124515-04; United States / NCI NIH HHS / CA / R21 CA132026-03; United States / NIMHD NIH HHS / MD / L60 MD001952; United States / NCI NIH HHS / CA / CA124515-01A1; United States / NCRR NIH HHS / RR / P20 RR018787; United States / NCI NIH HHS / CA / R01CA124515; United States / NCRR NIH HHS / RR / P20RR018787; United States / NCI NIH HHS / CA / R21 CA132026-01A1; United States / NCI NIH HHS / CA / R21 CA132026; United States / NCI NIH HHS / CA / CA124515-02; United States / NCI NIH HHS / CA / R01 CA124515-01A1; United States / NCI NIH HHS / CA / R01 CA124515-02; United States / NCI NIH HHS / CA / R21CA132026; United States / NCI NIH HHS / CA / R01 CA124515; United States / NCI NIH HHS / CA / R01 CA124515-05; United States / NCI NIH HHS / CA / R01 CA124515-03S1; United States / NCI NIH HHS / CA / CA132026-01A1; United States / NCI NIH HHS / CA / R01 CA124515-03; United States / NCI NIH HHS / CA / R01CA124515-S3; United States / NCI NIH HHS / CA / R21 CA132026-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; EC 3.5.3.1 / Arginase
  • [Number-of-references] 82
  • [Other-IDs] NLM/ NIHMS277625; NLM/ PMC3056209
  •  go-up   go-down


34. Bosquet JG, Merideth MA, Podratz KC, Nagorney DM: Hepatic resection for metachronous metastases from ovarian carcinoma. HPB (Oxford); 2006;8(2):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for metachronous metastases from ovarian carcinoma.
  • However, the role of hepatic resection in combination with secondary cytoreduction for epithelial ovarian cancer is unclear.
  • Patients with recurrent ovarian cancer and metachronous intrahepatic metastases are often evaluated by a multidisciplinary team at the Mayo Clinic comprising pelvic and hepatobiliary surgeons for consideration of cytoreductive surgery.
  • The purpose of this report is to update the outcome of cytoreductive surgery including hepatic resection for patients with metastatic ovarian carcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):273-80 [15491746.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1152-61 [15022281.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):278-87 [10053096.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):144-53 [10618617.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Gynecol Oncol. 1984 Jul;18(3):293-8 [6745731.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1606-14 [8635065.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):9-12 [8995540.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):45-51 [9234920.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1090-4 [11020885.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):171-5 [10926798.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):171-8 [9264559.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):504-12 [11733963.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Natl Cancer Inst Monogr. 1975 Oct;42:101-4 [1234624.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):16-21 [12694649.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):383-8 [14599870.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • (PMID = 18333253.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131426
  •  go-up   go-down


35. Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B: Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol; 2009 Apr;40(4):527-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported on higher expression of the insulin-like growth factor pathway genes IGF-II and IGFBP3 in serous ovarian/peritoneal carcinoma compared to malignant peritoneal mesothelioma.
  • Effusions (n = 327), including 294 carcinomas (205 ovarian, 48 breast, 17 cervical/endometrial, 12 lung, 12 gastrointestinal/genitourinary) and 33 malignant mesotheliomas, were immunostained for insulin-like growth factor-II and insulin-like growth factor binding protein-3.
  • Surgical ovarian carcinoma (n = 124) and peritoneal mesothelioma (n = 18) specimens were additionally studied.
  • Insulin-like growth factor binding protein-3 levels were measured in 148 effusion supernatants (114 ovarian carcinomas, 18 breast carcinomas, 16 mesotheliomas) using enzyme-linked immunosorbent assay.
  • Insulin-like growth factor binding protein-3 promoter methylation was analyzed in 11 ovarian carcinoma effusions.
  • In surgical specimens, insulin-like growth factor binding protein-3 expression was higher in ovarian carcinomas compared to peritoneal mesotheliomas (P = .007), whereas insulin-like growth factor-II expression was comparable (P = .505).
  • Insulin-like growth factor binding protein-3 levels by enzyme-linked immunosorbent assay were comparable in the 3 analyzed cancer types.
  • High insulin-like growth factor binding protein-3 expression in prechemotherapy and high insulin-like growth factor-II expression in postchemotherapy ovarian carcinoma effusions correlated with poor overall survival (P = .031 and P = .024, respectively).
  • In conclusion, insulin-like growth factor-II and insulin-like growth factor binding protein-3 are more frequently expressed in metastatic carcinomas compared to mesothelioma in effusions but are less specific than currently used markers.
  • Insulin-like growth factor-II and insulin-like growth factor binding protein-3 may be novel prognostic markers in metastatic ovarian carcinoma.
  • [MeSH-major] Ascitic Fluid / metabolism. Biomarkers, Tumor / analysis. Carcinoma / metabolism. Insulin-Like Growth Factor Binding Proteins / biosynthesis. Insulin-Like Growth Factor II / biosynthesis. Mesothelioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Insulin-Like Growth Factor Binding Protein 3. Kaplan-Meier Estimate. Middle Aged. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / mortality. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity. Tissue Array Analysis

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121847.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IGFBP3 protein, human; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Proteins; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


36. Yamano T, Morii E, Arai I, Takada T, Kubota K, Sato M, Inoue T, Okada Y, Hara T, Aozasa K: Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. Int J Clin Oncol; 2010 Dec;15(6):621-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis.
  • Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone.
  • We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma.
  • A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer.
  • She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer.
  • Histological analysis suggested primary ovarian cancer.
  • Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer.
  • The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers.
  • According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
  • Therefore, we determined that the ovarian tumor was metastatic.
  • Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
  • [MeSH-major] Liver Neoplasms / genetics. Liver Neoplasms / secondary. Mutation / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2006 Nov-Dec;92(6):491-5 [17260489.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):128-38 [18162780.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):85-7 [8990444.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(6):713-5 [15597848.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] J Thorac Oncol. 2008 Aug;3(8):931-4 [18670315.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5119-22 [1516069.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3674-8 [1319827.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3499-504 [10999735.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):784-91 [15541358.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Clin Colorectal Cancer. 2004 Feb;3(4):215-22 [15025793.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):695-8 [9869515.001]
  • [Cites] Diagn Mol Pathol. 1993 Mar;2(1):29-35 [8287223.001]
  • (PMID = 20514505.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


37. Burns KA, Kurian S, Burke CC: Evaluating patients with mildly elevated transaminase levels. Clin J Oncol Nurs; 2007 Aug;11(4):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE STUDY: S.B. is a 52-year-old woman with recurrent stage IV ovarian cancer.
  • A CA-125 blood test was elevated, and a computed tomography scan of the abdomen and pelvis revealed bilateral ovarian masses highly suspicious for malignancy.
  • Pathology revealed poorly differentiated papillary serous ovarian cancer.
  • Metastatic disease was noted in the rectosigmoid area and vaginal apex.
  • [MeSH-major] Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Cystadenoma, Papillary / metabolism. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / pathology. Vaginal Neoplasms

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723962.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Number-of-references] 19
  •  go-up   go-down


38. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA: Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer; 2007 Sep 15;110(6):1264-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
  • BACKGROUND: The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays.
  • In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
  • METHODS: Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting.
  • Sixty-two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry.
  • The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
  • RESULTS: LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001).
  • Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E-positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry.
  • CONCLUSIONS: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry.
  • The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / mortality. Cyclin E / analysis. Mesothelioma / chemistry. Mesothelioma / mortality. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / mortality


39. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
  • BRMS1 (breast cancer metastasis suppressor) has recently been identified as a metastasis-suppressor gene for human breast cancer and melanoma.
  • Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability.
  • Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo.
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


40. Iyibozkurt AC, Akhan SE, Topuz S, Citil I, Berkman S: Laparoscopic evaluation of metastatic ovarian cancer: a case report. Eur J Gynaecol Oncol; 2005;26(1):123-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic evaluation of metastatic ovarian cancer: a case report.
  • OBJECTIVE AND CASE: Both noninvasive and invasive methods have limited value in the diagnosis of metastatic ovarian cancer.
  • We present a case with the initial complaint of abdominal distention in whom primary and metastatic tumor sites were safely diagnosed by using laparoscopy: a gastric tumor with ovarian metastasis.
  • DISCUSSION: Diagnostic laparoscopy by the open technique provides a safe and effective diagnostic option in patients with metastatic ovarian cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Ovarian Neoplasms / diagnosis. Stomach Neoplasms / diagnosis


41. Chiu HH, Liu YW: Ovarian cancer metastatic to the rectum mimicking primary rectal carcinoma. Clin Gastroenterol Hepatol; 2006 Nov;4(11):xxvi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the rectum mimicking primary rectal carcinoma.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Rectal Neoplasms / diagnosis. Rectal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730238.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


42. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK: Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer; 2006 Sep 15;107(6):1407-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
  • BACKGROUND: Epithelial ovarian cancer demonstrates high mortality due to diagnosis at an advanced stage.
  • In the search for a biomarker for early diagnosis and a target for therapy, the issue of whether interleukin-13 receptor (IL-13R), shown to be expressed on a variety of human cancers, is expressed in ovarian tumor samples was explored.
  • METHODS: IL-13R expression in 15 normal and 68 ovarian tumor tissue samples was determined by immunohistochemistry.
  • The efficacy of IL-13R-directed cytotoxin was determined in mice with subcutaneous, orthotopic, and peritoneal metastatic ovarian cancer.
  • RESULTS: Immunohistochemical analyses revealed that 83% of ovarian cancer specimens express IL-13Ralpha2, a high-affinity IL-13R subunit chain, whereas normal ovary samples expressed none or very low levels.
  • The majority of clear cell ovarian carcinomas with the worst prognosis showed strong staining for IL-13Ralpha2.
  • IL-13 cytotoxin was highly cytotoxic to the IGROV-1 ovarian cancer cell line in vitro, and it mediated significant antitumor activity against a xenografted tumor model.
  • The antitumor effects were confirmed by treating orthotopically implanted or peritoneal metastatic ovarian tumors, which showed significant extension of survival in immunodeficient mice.
  • CONCLUSIONS: IL-13Ralpha2 is a promising target for ovarian cancer therapy, and the soluble form of IL-13R may be a possible surrogate marker for disease monitoring.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytotoxins / pharmacology. Interleukin-13 / pharmacology. Ovarian Neoplasms / drug therapy. Receptors, Interleukin / analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2006 by the American Cancer Society.
  • (PMID = 16902988.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytotoxins; 0 / IL13RA1 protein, human; 0 / Il13ra1 protein, mouse; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha1 Subunit; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-13
  •  go-up   go-down


43. Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J, Lau E, Wong J, Eu P, Hicks RJ, Prince HM: In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother; 2007 Feb;56(2):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.
  • We describe the use of two methods of cell labelling for tracking the destination of autologous-derived macrophage activated killer (MAK) cells linked to the bi-specific antibody MDX-H210 delivered either by intravenous (i.v.) or intraperitoneal (i.p.) injection in ten patients with peritoneal relapse of epithelial ovarian carcinoma.
  • MAK cell administration produced minimal infusional toxicity and demonstrated a reproducible pattern of in vivo distribution and active in vivo tracking to sites of known tumour following 8 of 16 i.v. infusions or 4 of 6 i.p. infusions.
  • This data demonstrates that cellular cancer immunotherapies may be successfully delivered to the sites of active tumour following either i.v. or i.p. injection in a proportion of patients with metastatic cancer.
  • [MeSH-major] Carcinoma / immunology. Carcinoma / secondary. Fluorodeoxyglucose F18 / administration & dosage. Killer Cells, Lymphokine-Activated / immunology. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733671.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indium Radioisotopes; 0 / MDX-H210 antibody; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Rossato M, Barban M, Vettor R: Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer. Int J Biol Markers; 2007 Apr-Jun;22(2):159-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer.
  • [MeSH-major] Insulin / blood. Ovarian Neoplasms / blood


45. Munakata R, Sawair FA, Cheng J, Saku T: Gingival metastasis of ovarian carcinoma: report of a case and review of the literature. Int J Oral Maxillofac Surg; 2009 Oct;38(10):1123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis of ovarian carcinoma: report of a case and review of the literature.
  • The authors report an unusual case of metastatic ovarian carcinoma in the gingiva of a 46-year-old woman 5 years after ovariectomy.
  • The diagnosis of metastatic ovarian mucinous cystadenocarcinoma was made.
  • A review of the English literature revealed this to be the first report of gingival metastasis of an ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / secondary. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505797.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 0 / Receptors, Estrogen; 0 / Vimentin
  • [Number-of-references] 27
  •  go-up   go-down


46. Fu X, Tao L, Zhang X: An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther; 2007 May;14(5):480-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
  • Oncolytic viruses derived from herpes simplex virus (HSV) have shown considerable promise as antitumor agents against solid tumors including ovarian cancer.
  • In the study reported here, we administered this HSV-2-derived virus intraperitoneally (i.p.) to nude mice bearing metastatic human ovarian tumor xenografts, evaluated its oncolytic activity, and compared with to that of a virus constructed from HSV-1.
  • We conclude that i.p. administration of this HSV-2-based oncolytic virus may provide effective treatment for metastatic human ovarian cancer.
  • [MeSH-major] Herpesvirus 2, Human. Oncolytic Virotherapy / methods. Oncolytic Viruses. Ovarian Neoplasms / therapy


47. Sengupta S, Michener CM, Escobar P, Belinson J, Ganapathi R: Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion. Gynecol Oncol; 2008 May;109(2):226-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.
  • OBJECTIVES: To identify proteins unique to metastatic ovarian cancer and test their potential involvement in cell adhesion.
  • METHODS: We purified plasma membrane from paired metastatic and primary tumor tissues from patients with stage IIIC ovarian cancer.
  • The role of one of the identified proteins, ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1) in cell adhesion was determined in the presence of LPA using both over-expression and down regulation approaches.
  • RESULTS: We identified a differentially expressed 29 kDa protein as OCIAD1 over-expressed in metastatic tissues, when compared to primary tumor tissues.
  • OCIAD1 over-expression in HEY ovarian cancer cells increased LPA-induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin 10/11.
  • CONCLUSIONS: This is the first report that OCIAD1 is over-expressed in metastatic ovarian cancer tissues.
  • The effect of OCIAD1 on cell adhesion may be related to its function in ovarian cancer.
  • Failure of paclitaxel to affect ovarian cancer cell adhesion in presence of OCIAD1 raises the possibility of OCIAD1's role in tumor metastasis.
  • Ongoing studies using a mouse orthotopic LPA-dependent ovarian cancer metastasis model are focused on strategies to inhibit the potential role of OCIAD1 in tumor metastasis.
  • [MeSH-major] Adenocarcinoma / physiopathology. Neoplasm Proteins / metabolism. Ovarian Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328549.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Collagen Type I; 0 / Laminin; 0 / Lysophospholipids; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / ovarian cancer immuno-reactive antigen domain containing 1, human; 22002-87-5 / lysophosphatidic acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


48. Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G: Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol; 2010 Nov;21(11):2201-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
  • BACKGROUND: Ovarian cancer is the leading cause of death in women with gynecological malignancies.
  • Brain metastases are considered an uncommon metastatic site.
  • PATIENTS AND METHODS: A multicenter retrospective chart review was carried out including all patients with histologically confirmed ovarian cancer from six different German hospitals from 1981 to 2008.
  • Overall, 4277 cases of patients with ovarian cancer were screened and patients with brain metastasis were identified and analyzed regarding various clinical variables and survival.
  • CONCLUSIONS: Platinum sensitivity is the most important prognostic factor in patients with ovarian cancer metastatic to the brain.
  • This novel finding should be considered in the strategy of multimodal therapy for brain metastases in ovarian cancer.


49. Simpkins F, Zahurak M, Armstrong D, Grumbine F, Bristow R: Ovarian malignancy in breast cancer patients with an adnexal mass. Obstet Gynecol; 2005 Mar;105(3):507-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian malignancy in breast cancer patients with an adnexal mass.
  • OBJECTIVE: The objectives of this study were to estimate ovarian malignancy rate in breast cancer patients with an adnexal mass and to identify variables predictive of malignancy.
  • METHODS: This was a review from 1990-2002 including women with breast cancer diagnosed with an adnexal mass who subsequently underwent oophorectomy.
  • Ovarian pathology was classified as benign, primary malignancy, or metastatic breast cancer.
  • RESULTS: Of 129 cases reviewed, benign ovarian cysts were found in 113 cases (88%) and malignant ovarian neoplasms were found in 16 cases (12%).
  • Women with estrogen-receptor-negative breast cancer had an increased risk for malignant adnexal masses (44%; OR 12.4, 95% confidence interval 2.4-65.1; P = .003).
  • Malignant adnexal masses had a greater likelihood of being primary ovarian cancer than metastatic breast cancer by 7:1.
  • CONCLUSION: An isolated adnexal mass in the breast cancer patient is most commonly a benign ovarian cyst.
  • [MeSH-major] Breast Neoplasms. Neoplasms, Multiple Primary. Ovarian Cysts / complications. Ovarian Neoplasms


50. Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS: Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci; 2009 Feb;24(1):114-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of metastatic tumors to the ovaries.
  • Approximately 5-30% of the ovarian cancers are metastatic malignancies.
  • The prevalence of metastatic ovarian tumors varies with the incidence rates and spread patterns of primary malignancies.
  • We evaluated the prevalence, pre- and postoperative characteristics of metastatic ovarian cancer in Korean women.
  • We reviewed the records for 821 ovarian malignancies with pathological consultation from 1996-2006 and recorded patient demographical, radiological, histopathological, and survival data.
  • The study included 112 cases of histologically confirmed metastatic ovarian cancer.
  • Metastatic ovarian cancer accounted for 13.6% of all ovarian malignancy, primarily arising from the gastrointestinal tract.
  • The differential diagnosis of metastatic ovarian cancer can be problematic, so multiple diagnostic approaches are necessary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):213-8 [11274559.001]
  • [Cites] Abdom Imaging. 2007 Nov;32(6):784-95 [17318680.001]
  • [Cites] Oncology. 2002;63(2):124-9 [12239446.001]
  • [Cites] J Ultrasound Med. 2003 Mar;22(3):243-7 [12636323.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):397-401 [12893207.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):87-91 [15047218.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):477-82 [15297191.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):69-73 [15665686.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S99-111 [15492758.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3766-72 [15897574.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):235-41 [15982725.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):97-101 [16278010.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:132-8 [16515581.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):511 [16622117.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3B):2339-44 [16821613.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):193-200 [17466362.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):78-82 [17049712.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):105-9 [11426970.001]
  • (PMID = 19270823.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC2650975
  • [Keywords] NOTNLM ; Diagnostic Imaging / Metastasis / Ovary / Prevalence / Surgical Procedures
  •  go-up   go-down


51. Yeung KK, Coster E, Floris Vos AW, Van der Vijgh RK, Linsen MA, Wisselink W: Repeated arterial thrombosis as a complication of carboplatin-based chemotherapy. Vascular; 2006 Jan-Feb;14(1):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of a 57-year-old woman with repeated acute arterial thrombosis of the femoral arteries following intravenous carboplatin-based combination chemotherapy for metastatic ovarian carcinoma.
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Radiography. Recurrence

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849025.001).
  • [ISSN] 1708-5381
  • [Journal-full-title] Vascular
  • [ISO-abbreviation] Vascular
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


52. Buyukkurt S, Altintas A, Gumurdulu D, Zeren H, Guzel B: Mucoepidermoid carcinoma of the parotid gland with ovarian and peritoneal metastasis. J Obstet Gynaecol Res; 2008 Apr;34(2):271-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the parotid gland with ovarian and peritoneal metastasis.
  • Metastatic ovarian carcinoma generally arises from the gastrointestinal tract.
  • Mucoepidermoid carcinoma is the most common malignant tumor of the salivary gland.
  • Distant metastasis of the parotid mucoepidermoid carcinoma is very rare, and it usually occurs to the lungs, bones and liver.
  • A 28-year-old woman with a history of high grade mucoepidermoid carcinoma of the parotid gland was admitted with ascites and bilateral ovarian masses.
  • Nevertheless, pathological examination of the ovaries revealed a metastasis from the mucoepidermoid carcinoma.
  • Metastatic ovarian tumors usually originate from the gastrointestinal tract.
  • [MeSH-major] Carcinoma, Mucoepidermoid / secondary. Ovarian Neoplasms / secondary. Parotid Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18412796.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Ben-Zvi N, Shani A, Ben-Baruch G, Agmon-Levin N, Sthoeger Z, Huszar M, Ben-Arie A, Dgani R: Dermatomyositis following the diagnosis of ovarian cancer. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1124-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatomyositis following the diagnosis of ovarian cancer.
  • We present a case history of a woman who developed dermatomyositis following the diagnosis of stage IV ovarian cancer.
  • Dermatomyositis is a rare paraneoplastic syndrome that usually precedes the diagnosis of ovarian cancer by several months or years.
  • Ours is the fifth reported case of dermatomyositis after an established diagnosis of ovarian cancer in the literature.
  • [MeSH-major] Dermatomyositis / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / pathology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343193.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Immunosuppressive Agents
  •  go-up   go-down


54. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Pölcher M, Grünn U, Leutner C, Pötzsch B, Kuhn W: Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol; 2007 May;8(5):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma, Papillary / therapy. Carrier Proteins / genetics. Cystadenocarcinoma, Serous / therapy. Dendritic Cells / transplantation. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy. RNA, Messenger / therapeutic use. Receptors, Cell Surface / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466904.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 935E97BOY8 / Folic Acid
  •  go-up   go-down


55. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A: An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics; 2009 Jun;10(4):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings.
  • Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers.
  • Ovarian tumors can be classified on the basis of the cells of origin in epithelial, stromal and germ cell tumors.
  • Epithelial ovarian tumors display great histological heterogeneity and can be further subdivided into benign, intermediate or borderline, and invasive tumors.
  • Several studies on ovarian tumors, have focused on the identification of both diagnostic and prognostic markers for applications in clinical practice.
  • High-throughput technologies have accelerated the process of biomolecular study and genomic discovery; unfortunately, validity of these should be still demonstrated by extensive researches on sensibility and sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management.
  • In this review, the current state of knowledge about the genoproteomic and potential clinical value of gene expression profiling in ovarian cancer and ovarian borderline tumors is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian cancers and borderline tumors, identifying different genotypes of ovarian tissue and identifying proteins linked to cancer or tumor development.
  • By these targets, authors focus on the use of novel molecules, developed on the proteomics and genomics researches, as potential protein biomarkers in the management of ovarian cancer or borderline tumor, overlooking on current state of the art and on future perspectives of researches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):568-74 [11709277.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):282-5 [11553857.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23 [11416160.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4965-8 [11326648.001]
  • [Cites] Oncogene. 2009 Mar 5;28(9):1206-17 [19151754.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):475-80 [19150122.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1034-45 [18930836.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1353-60 [18951210.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 15;76(6):707-16 [18644348.001]
  • [Cites] Endocrinology. 2008 Aug;149(8):3809-16 [18450971.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2102-11 [18396168.001]
  • [Cites] Histol Histopathol. 2008 Aug;23(8):935-44 [18498068.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):695-705 [18505915.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4127-34 [17939699.001]
  • [Cites] Micron. 2007;38(8):824-33 [17709250.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):725-31 [17610223.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2509-17 [17547437.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1993-2002 [17620429.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Ann Oncol. 2007 May;18(5):881-5 [17301071.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):10-5 [17197890.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):924-31 [16842844.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9017-25 [16982743.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1407-18 [16902988.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):433-47 [16885651.001]
  • [Cites] EMBO Rep. 2006 Jun;7(6):599-604 [16741504.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):171-6 [16620064.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):397-406 [16549852.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):62-70 [16445817.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9338-43 [16361633.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Am J Obstet Gynecol. 2005 Nov;193(5):1630-9 [16260202.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] Mol Endocrinol. 2005 Oct;19(10):2564-78 [15928314.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):618-23 [16014115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1729-36 [15841084.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Nat Med. 1999 Aug;5(8):938-42 [10426319.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):849-51 [10216504.001]
  • [Cites] Clin Chem. 1999 May;45(5):651-8 [10222351.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6379-83 [2819873.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):35-49 [15027884.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):761-8 [14984938.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1067-78 [14578472.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):433-73 [12663865.001]
  • [Cites] Nature. 2002 Nov 7;420(6911):19 [12422186.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):41-7 [11163149.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):103-8 [17479670.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):83-8 [17479666.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1440-50 [17315909.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1295-305 [17291023.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5 [17403417.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1670-9 [17308108.001]
  • [Cites] Trends Biotechnol. 2007 Mar;25(3):111-8 [17257698.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):772-80 [17269733.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4943-8 [17214367.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):47-59 [11960694.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S23-9 [11895152.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • (PMID = 19949545.001).
  • [ISSN] 1875-5488
  • [Journal-full-title] Current genomics
  • [ISO-abbreviation] Curr. Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2709935
  • [Keywords] NOTNLM ; Ovarian cancer / borderline ovarian tumors / genomics / markers / oncogenes. / proteomics
  •  go-up   go-down


56. Wang S, Ma XY, Xia Y, Zhang LH: [Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul;41(4):575-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors].
  • OBJECTIVE: To analyze the expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors and their relationship with clinical pathological features.
  • METHODS: The expressions of Ki67, PCNA protein and mitotic index in ovarian tissues from 20 patients with normal ovarian tissues, 28 patients with ovarian benign tumors, 20 patients with borderline tumors and 109 (73 metastatic ovarian cancer) patients with malignant tumors were retrospectively tested using the American GBI immunohistochemistry two-step method.
  • The expressions of Ki67 and PCNA mRNA were also detected by in situ hybridization (ISH) in ovarian tissues from 37 patients with primary ovarian cancer, 14 patients with borderline tumors, 11 patients with benign tumors and 12 patients with normal ovarian tissues.
  • The relationship between clinical pathologic parameters and the expressions of Ki67 and, PCNA and mitotic index in human ovarian tumors was analyzed. RESULTS:.
  • (1) The expressions of Ki67 mRNA and protein in ovarian epithelial tumors was higher than in the controls (P = 0.003; P = 0.009; P = 0.001; P = 0.001).
  • 014). (2) The expression of Ki67 in ovarian epithelial was higher in low differential carcinoma and at FIGO III-IV stage (P = 0.008; P = 0.007).
  • The expression of Ki67 protein in serous tumor tissues was high, but low or missed in other types of tumor tissues such as malignant mixed mullerian tumor and transitional cell carcinoma (P = 0. 018).
  • The high expression of PCNA did not coincide with histological grading, clinical stage and histological types (P = 0.447; P = 0.763; P = 0.657).
  • The high expression of mitotic index coincided with histological grading and clinical stage, but not with histological types (P = 0.002; P = 0.040). (3) The combined overexpression of Ki67 and high mitotic index occurred in 57 patients, which coincided with histological grading, clinical stage and histological types (P = 0.018; P = 0.001; P = 0.020). (4) In the 73 patients with metastatic ovarian cancers, the expressions of Ki67 (58.9%), PCNA protein (91.8%) and high MI (61.6%) in primary cancer tissues were greater than in the metastatic cancer tissues (peritoneum and epiploon, Ki67 41.4%, P = 0.031; PCNA 74%, P = 0.004; high MI 38.4%, P = 0.005).
  • The positive intensity of Ki67 protein expression in primary ovarian cancers was significantly higher than in metastatic ovarian cancers (P = 0.040).
  • There was no significant difference in positive intensity of PCNA between primary and metastatic ovarian cancers (P = 0.514).
  • CONCLUSION: Ki67 and mitotic index can serve as biomolecular markers for predicting the proliferation of malignant ovarian epithelial tumors.
  • PCNA can not discriminate between benign and malinant ovarian tumors.
  • [MeSH-major] Ki-67 Antigen / metabolism. Mitotic Index. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Carcinoma / metabolism. Carcinoma / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20848772.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; Ovarian epithelial cancer
  •  go-up   go-down


57. Kehoe SM, Eisenhauer EL, Chi DS: Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. Gynecol Oncol; 2008 Nov;111(2 Suppl):S51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with advanced-stage ovarian cancer often have metastatic disease in the upper abdominal region.
  • A comprehensive approach to surgical cytoreduction, which has been associated with improved survival in patients with advanced ovarian cancer, should incorporate upper abdominal resection.
  • [MeSH-major] Abdomen / anatomy & histology. Abdomen / surgery. Abdominal Neoplasms / secondary. Abdominal Neoplasms / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801559.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Duong HV, McLean IW, Beahm DE: Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol; 2006 Oct;142(4):693-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma.
  • PURPOSE: To report a case of metastatic malignant amelanotic melanoma to the skin from a patient diagnosed with bilateral diffuse uveal melanocytic proliferation (BDUMP).
  • She had previously been diagnosed with ovarian carcinoma, and findings of funduscopic examinations were consistent with BDUMP.
  • Metastatic examination revealed no evidence of liver involvement.
  • RESULTS: The hematoxylin and eosin, S-100, and HMB-45 stains were consistent with metastatic malignant amelanotic melanoma to the skin.
  • CONCLUSIONS: Although believed to have a low potential for metastasis, patients should be monitored and evaluated regularly to detect any new lesions not associated with their primary inciting carcinoma.
  • [MeSH-major] Melanocytes / pathology. Melanoma, Amelanotic / secondary. Ovarian Neoplasms / pathology. Paraneoplastic Syndromes / pathology. Skin Neoplasms / secondary. Uveal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011873.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


59. Gervais DA, Arellano RS, Mueller PR: Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. AJR Am J Roentgenol; 2006 Sep;187(3):746-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management.
  • OBJECTIVE: Stages III and IV ovarian cancer are treated with a combination of chemotherapy and resection, in some cases including second and third surgical procedures, to achieve cytoreduction.
  • We report early experience with percutaneous radiofrequency ablation in the management of isolated foci of metastatic ovarian cancer and assess the efficacy of the technique in achieving and maintaining local control by percutaneous cytoreduction.
  • CONCLUSION: Percutaneous radiofrequency ablation is effective in achieving local control in selected patients with metastasis from ovarian cancer.
  • [MeSH-major] Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Ovarian Neoplasms / pathology


60. Chang CL, Ma B, Pang X, Wu TC, Hung CF: Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther; 2009 Aug;17(8):1365-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.
  • Metastatic ovarian cancer is the leading cause of death among women with gynecologic malignancies in the United States.
  • The lack of effective treatment for patients with advanced ovarian cancer warrants development of innovative therapies.
  • Cancer therapy using oncolytic viruses represents a promising new approach for controlling tumors.
  • Thus, the combination of Cox-2 inhibitors and vaccinia virus represents a potential innovative approach to controlling ovarian tumors.
  • [MeSH-major] Cyclooxygenase 2 Inhibitors / therapeutic use. Oncolytic Virotherapy / methods. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / therapy. Vaccinia virus / physiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):56-65 [18506760.001]
  • [Cites] J Immunother. 2001 Jan-Feb;24(1):46-57 [11211148.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2998-3005 [11595687.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5405-7 [12359744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):886-94 [12377342.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1547-9 [12824303.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91 [14693742.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3668-78 [15150127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11671-5 [8524826.001]
  • [Cites] Nat Med. 1999 Aug;5(8):881-7 [10426310.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):803-10 [15499625.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2619-26 [15728468.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2504-9 [15454489.001]
  • [Cites] World J Gastroenterol. 2005 Jun 28;11(24):3724-8 [15968728.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9501-9 [16230415.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):214-22 [16397045.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6432-8 [16778222.001]
  • [Cites] Arch Med Res. 2006 Aug;37(6):689-95 [16824926.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7811-9 [17114452.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):433-42 [17097285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):888-96 [17293239.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3185-91 [17409426.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):639-46 [17579086.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):791-800 [17582802.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3350-8 [17965776.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1523-31 [17971769.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):347-58 [17668203.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2071-5 [18381410.001]
  • [Cites] Lancet Oncol. 2008 Jun;9(6):533-42 [18495536.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 1;76(5):662-71 [18644347.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1637-42 [18628758.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):141-51 [19139123.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):585-91 [10753190.001]
  • (PMID = 19471247.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors
  • [Other-IDs] NLM/ PMC2835247
  •  go-up   go-down


61. Abood G, Bowen M, Potkul R, Aranha G, Shoup M: Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg; 2008 Mar;195(3):370-3; discussion 373
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for recurrent metastatic ovarian cancer.
  • BACKGROUND: The role for liver resection in metastatic ovarian cancer has not been defined.
  • The aim of the current study was to investigate the validity of hepatic resection as a treatment option in metastatic ovarian cancer.
  • METHODS: Retrospective review of a single institution's experience of patients undergoing hepatic resection for metastatic ovarian cancer from 1998-2006.
  • RESULTS: Ten patients underwent resection for metastatic ovarian cancer.
  • CONCLUSION: Liver resection for metastatic ovarian cancer is safe and is associated with long-term survival in some patients.
  • [MeSH-major] Hepatectomy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery


62. Cowden Dahl KD, Zeineldin R, Hudson LG: PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res; 2007 May;5(5):413-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.
  • Elevated expression of the epidermal growth factor (EGF) receptor (EGFR) is detected in human ovarian tumors and is associated with decreased recurrence-free and overall survival.
  • PEA3, an ETS family transcription factor, is elevated in advanced and metastatic ovarian cancer and regulates MMPs in various cell types, therefore, we investigated whether PEA3 is required for the EGFR-dependent induction of MMP mRNA.
  • MMP-9 and MMP-14 mRNA levels were selectively increased in response to EGFR activity in ovarian tumor cells.
  • Furthermore, PEA3 overexpression was sufficient to induce MMP-9 and MMP-14 mRNA, tumor cell migration, and invasion, suggesting that PEA3 is an important contributor to the metastatic phenotype.
  • These results suggest that PEA3 is regulated by EGFR and that the elevated PEA3 expression detected in human ovarian cancer may divert cells to a more invasive phenotype by regulating MMP-9 and MMP-14.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1493-500 [11717538.001]
  • [Cites] J Rheumatol. 2001 Jul;28(7):1631-9 [11469472.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1375-84 [11562388.001]
  • [Cites] Int J Gynecol Pathol. 1992 Oct;11(4):266-72 [1399232.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1951-7 [8280488.001]
  • [Cites] Br J Cancer. 1996 Feb;73(3):301-6 [8562334.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10672-80 [8631874.001]
  • [Cites] Cancer Lett. 1996 Sep 10;106(2):185-91 [8844971.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):60-8 [8986534.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):222-33 [9119388.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):937-52 [9285689.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Mol Carcinog. 1998 Mar;21(3):194-204 [9537651.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):331-7 [9766568.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):221-8 [9888461.001]
  • [Cites] J Biol Chem. 1999 Feb 12;274(7):4347-53 [9933637.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5588-96 [10026175.001]
  • [Cites] Oncogene. 1999 Mar 4;18(9):1771-6 [10208438.001]
  • [Cites] Prostate. 1999 Aug 1;40(3):159-66 [10398277.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):715-20 [15756447.001]
  • [Cites] Reproduction. 2005 May;129(5):651-7 [15855628.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9280-6 [16230389.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):79-87 [16546322.001]
  • [Cites] Mol Carcinog. 2006 Nov;45(11):851-60 [16788982.001]
  • [Cites] J Cell Sci. 2002 Feb 15;115(Pt 4):839-48 [11865039.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Methods. 2002 Jan;26(1):27-36 [12054902.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1412-9 [12684413.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):469-76 [12851697.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13 [14967450.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20794-806 [14990565.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1565-72 [15138601.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):397-414 [15277215.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):418-24 [15238978.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):188-99 [15279711.001]
  • [Cites] Clin Exp Metastasis. 2004;21(3):191-9 [15387369.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1583-92 [1923525.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):529-35 [1548517.001]
  • [Cites] Int J Cancer. 1992 Sep 9;52(2):218-24 [1325950.001]
  • [Cites] Mol Pharmacol. 2000 Jul;58(1):145-51 [10860936.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):799-808 [11089877.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1370-83 [11158322.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1855-61 [11280738.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):551-7 [11297247.001]
  • (PMID = 17475671.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA119729-01; United States / NCI NIH HHS / CA / P20 CA888070; United States / NCI NIH HHS / CA / F32 CA119729; United States / NCI NIH HHS / CA / F32 CA119729-02; United States / NIEHS NIH HHS / ES / P30 ES012072; United States / NCI NIH HHS / CA / 1F32CA119729-01; United States / NCI NIH HHS / CA / R01 CA090492; United States / NCI NIH HHS / CA / CA119729-02; United States / NIEHS NIH HHS / ES / P30 ES-012072; United States / NCI NIH HHS / CA / CA119729-01; United States / NCI NIH HHS / CA / R01 CA90429
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transcription Factors; 0 / transcription factor PEA3; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS452280; NLM/ PMC3621069
  •  go-up   go-down


63. dos Santos LA, Modica I, Flores RM, D'Angelica M, Aghajanian C, Chi DS, Abu-Rustum NR: En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. Gynecol Oncol; 2006 Sep;102(3):596-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report.
  • INTRODUCTION: Multiple series have demonstrated the feasibility of full-thickness diaphragm resection for ovarian cancer metastatic to the diaphragm.
  • DISCUSSION: En bloc full-thickness diaphragm resection including a portion of lung tissue using the EndoGIA stapler is a safe, feasible, and effective method to optimize cytoreduction with disease-free margins in the context of invasive diaphragmatic ovarian cancer metastasis.
  • [MeSH-major] Diaphragm / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Ovarian Neoplasms / pathology. Thoracic Neoplasms / secondary


64. Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H: p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer; 2009 Jul 15;125(2):339-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer.
  • The aim of this study is to investigate p16INK4a expression by immunocytochemistry for ascites in advanced ovarian cancer and explore the possibility to predict chemotherapeutic response and prognosis.
  • The immunocytochemical study was performed on cytology of ascites obtained from 37 Stage III or Stage IV ovarian cancer patients with measurable disease before platinum/taxane-based first-line chemotherapy following primary cytoreductive surgery or as neoadjuvant chemotherapy.
  • In vitro expression of p16INK4a protein was also examined for both parent chemosensitive and acquired chemoresistant ovarian cancer cell lines.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ascites / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19330839.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


65. Zivanovic O, Barakat RR, Sabbatini PJ, Brown CL, Konner JA, Aghajanian CA, Abu-Rustum NR, Levine DA: Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up. Cancer; 2008 Jun 15;112(12):2690-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
  • BACKGROUND: The aim was to determine the long-term outcome for patients with FIGO stage IV epithelial ovarian carcinoma (EOC) treated with intraperitoneal (IP) chemotherapy after second-look assessment.
  • METHODS: By using data from a retrospective cohort of 433 patients who received IP therapy after second-look assessment after primary surgery and initial systemic therapy for EOC between 1984 and 1998 at our institution, all FIGO stage IIIC and IV patients were identified.
  • RESULTS: Overall, 297 patients met study criteria (246 stage IIIC; 51 stage IV).
  • The median survival for patients with stage IV disease was 34 months compared with 42 months for patients with stage IIIC disease (P=.02).
  • The only significant predictor of overall survival in patients with stage IV disease was the presence of gross residual disease at initiation of IP therapy (P=.027).
  • When comparing stage IV patients with and without pleural effusions to all stage IIIC patients, there was a significant trend toward improved survival in the patients with pleural effusions only compared with other stage IV patients (P=.01).
  • When compared with similarly treated stage IIIC patients, stage IV patients with malignant pleural effusions appear to have a better outcome than those with other sites of metastasis.
  • Future prospective trials should evaluate the use of IP therapy for patients with stage IV EOC by virtue of malignant pleural effusions only who responded to initial systemic therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Ovarian Neoplasms / drug therapy


66. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA: How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol; 2007 Oct;110(4):841-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The performance characteristics of the ACOG/SGO referral guidelines for detection of primary and metastatic ovarian cancer were calculated by using menopausal status, CA 125 level, imaging results, physical findings, and family history.
  • Forty-four percent (263/597) of postmenopausal women were diagnosed with ovarian cancer, whereas 20% (48/240) of premenopausal women had ovarian cancer.
  • Seventy-four percent of primary cancers were stage III or IV.
  • The referral guidelines performed better for late-stage than early-stage cancers in both sensitivity and positive predictive value, especially in postmenopausal women.
  • Although only 28 patients would not have been referred by the guidelines, the majority of these had early stage (I or II) disease.
  • CONCLUSION: The ACOG/SGO guidelines perform well in predicting advanced-stage ovarian cancer, probably owing to the nature of advanced-stage disease.
  • The guidelines perform poorly in identifying early-stage disease, especially in premenopausal women, primarily due to lack of early markers and signs of ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Practice Guidelines as Topic / standards. Referral and Consultation / standards


67. Brunisholz Y, Miller J, Proietto A: Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):606-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution.
  • The management of stage IV epithelial ovarian carcinoma remains controversial.
  • A retrospective database and casenote review was performed on all patients diagnosed with stage IV disease over a ten-year period (1992-2002).
  • Debulking surgery can be performed in patients with stage IV ovarian cancer, with an acceptable level of morbidity.
  • [MeSH-major] Neoplasm Metastasis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014113.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Walker J, Lane P: Challenges and choices: an audit of the management of nausea, vomiting and bowel obstruction in metastatic ovarian cancer. Contemp Nurse; 2007 Dec;27(1):39-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and choices: an audit of the management of nausea, vomiting and bowel obstruction in metastatic ovarian cancer.
  • Women living with metastatic ovarian cancer experience many distressing symptoms, such as vomiting and bowel obstruction, which challenge the expertise of nurses working in Palliative Care to promote quality of life.
  • [MeSH-major] Intestinal Obstruction / therapy. Medical Audit. Nausea / therapy. Ovarian Neoplasms / physiopathology. Vomiting / therapy


69. Wang Q, Li XG, Zhang Y, Cao LQ, Deng ZH, Chen Y: [Expression of EVEC in ovarian carcinoma and its biological significance]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):676-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of EVEC in ovarian carcinoma and its biological significance].
  • OBJECTIVE: To investigate the expression of EVEC in ovarian carcinoma and explore its biological significance.
  • METHODS: The expression of EVEC in 22 specimens of normal ovarian tissues and 63 specimens of ovarian cancers was detected by RT-PCR and Western blotting analysis, respectively.
  • RESULTS: RT-PCR showed that the expression level of EVEC in stage I-II ovarian cancer (0.199 ± 0.014) was significantly higher than that in stage III-IV ovarian cancer (0.155 ± 0.015, P < 0.05), and significantly lower than that in normal ovarian tissues (0.415 ± 0.055, P < 0.05).
  • There was no significant difference between the expression levels of EVEC in primary sites and that in corresponding metastatic sites of ovarian cancer (P > 0.05).
  • Furthermore, the results of Western blot also showed that the protein expression level of EVEC in stage I-II ovarian cancer was also significantly lower than that in normal ovarian tissues (0.179 ± 0.026 vs. 0.543 ± 0.032, P < 0.05), and higher than that in stage III-IV ovarian cancer (0.179 ± 0.026 vs. 0.115 ± 0.023, P < 0.05).
  • The EVEC expression level in the epiploic metastasis of stage I-II ovarian cancer was significantly higher than that of stage III-IV ovarian cancer (0.201 ± 0.028 vs. 0.101 ± 0.037, P < 0.05).
  • The expression of EVEC in ovarian carcinoma had no correlation with age, pathologic classification and histological grade (P > 0.05).
  • CONCLUSIONS: EVEC is closely related with carcinoma metastasis.
  • The expression of EVEC in ovarian cancer and its metastatic sites was remarkably decreased.
  • EVEC may play a negative role in the development and metastasis of ovarian cancer and may be a valuable marker in estimation of the prognosis for patients.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Extracellular Matrix Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Female. Humans. Middle Aged. Neoplasm Staging. Omentum / metabolism. Ovary / metabolism. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122382.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 0 / FBLN5 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


70. Chen MY, Ng KK, Ma SY, Wu TI, Chang TC, Lai CH: False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: a case report. Eur J Gynaecol Oncol; 2005;26(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: a case report.
  • We report a case of a 47-year-old woman with a false-positive [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) result caused by retained gauze during resection of liver metastasis for a Stage IV ovarian cancer at primary cytoreductive surgery.
  • However, the former proved to be recurrent ovarian cancer with the latter proven false-positive.
  • [MeSH-major] Adenocarcinoma, Papillary / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Surgical Sponges

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122202.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Kim SJ, Toma HS, Thirkill CE, Dunn JP Jr: Cancer-associated retinopathy with retinal periphlebitis in a patient with ovarian cancer. Ocul Immunol Inflamm; 2010 Apr;18(2):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-associated retinopathy with retinal periphlebitis in a patient with ovarian cancer.
  • PURPOSE: To describe a case of cancer-associated retinopathy (CAR) due to ovarian cancer presenting with retinal periphlebitis and a negative-type pattern electroretinogram (ERG).
  • RESULTS: A negative-type ERG in the setting of progressive vision loss and retinal periphlebitis led to the discovery of metastatic ovarian cancer and ultimately the diagnosis of CAR.
  • [MeSH-major] Carcinoma / complications. Ovarian Neoplasms / complications. Phlebitis / diagnosis. Retinal Diseases / diagnosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20370338.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / 1 P30 EY12576-05
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; VB0R961HZT / Prednisone
  •  go-up   go-down


72. Klein RL, Brown AR, Gomez-Castro CM, Chambers SK, Cragun JM, Grasso-Lebeau L, Lang JE: Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review. J Cancer; 2010;1:27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review.
  • Background. Primary ovarian carcinoma with metastasis to the breast is rare, with only 39 cases reported in the current literature.
  • Ovarian metastasis to the breast presenting as inflammatory breast carcinoma is even more infrequent, with only 6 cases reported.Case.
  • We present a patient who developed metastatic inflammatory cancer of the breast from a stage IIIC papillary serous ovarian adenocarcinoma approximately 1 year after the original diagnosis.
  • Pathologic analysis confirmed the origin of the tumor: a high-grade adenocarcinoma morphologically similar to the previously diagnosed ovarian cancer.
  • In addition, the tumor was strongly positive on immunohistochemistry for CA-125, identical to the ovarian primary.
  • Although ovarian metastasis to the breast presenting as inflammatory breast cancer is rare, it should be included in the differential diagnosis for any patient with a personal history of ovarian cancer.
  • Accurate differentiation is necessary because treatment differs significantly for patients with ovarian metastasis to the breast, as compared with patients with primary inflammatory breast cancer.
  • Ovarian metastasis to the breast confers a poor prognosis: patient survival ranged from 3 to 18 months, with a median survival of 6 months after the diagnosis of the breast metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842221.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2931350
  • [Keywords] NOTNLM ; breast cancer / breast cancer metastasis / inflammatory breast cancer / ovarian cancer / ovarian cancer metastasis
  •  go-up   go-down


73. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA: MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol; 2006 Mar;43(8):1129-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MT110 induced a costimulation independent polyclonal activation of CD4- and CD8-positive T cells as seen by de novo expression of CD69 and CD25, and secretion of interferon gamma, tumor necrosis factor alpha, and interleukins 2, 4 and 10.
  • MT110 was highly efficacious in a NOD/SCID mouse model with subcutaneously growing SW480 human colon cancer cells.
  • Finally, MT110 could eradicate patient-derived metastatic ovarian cancer tissue growing under the skin of NOD/SCID mice.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139892.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / MT110 monoclonal antibody; 0 / Recombinant Proteins; 0 / Single-Chain Antibodies
  •  go-up   go-down


74. Hurtado A, Tseng JC, Meruelo D: Gene therapy that safely targets and kills tumor cells throughout the body. Rejuvenation Res; 2006;9(1):36-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors studied the therapeutic value of Sindbis vectors for advanced metastatic cancer by using a variety of clinically accurate mouse models and demonstrated through imaging, histological, and molecular data that Sindbis vectors systemically and specifically infect/detect and kill metastasized tumors in vivo, leading to significant suppression of tumor growth and enhanced survival.
  • Use of two different bioluminescent genetic markers for the IVIS Imaging System (Xenogen Corp., Alameda, CA) permitted demonstration of an excellent correlation between vector delivery and metastatic locations in vivo.
  • These results suggest that Sindbis viral vectors may be promising agents for both specific detection and growth suppression of metastatic ovarian cancer.
  • [MeSH-major] Genetic Therapy. Genetic Vectors. Ovarian Neoplasms / therapy. Sindbis Virus

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608394.001).
  • [ISSN] 1549-1684
  • [Journal-full-title] Rejuvenation research
  • [ISO-abbreviation] Rejuvenation Res
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100687; United States / NCI NIH HHS / CA / CA22247; United States / NCI NIH HHS / CA / CA68498
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


75. Xu S, Mou H, Gu L, Su D, Zhu C, Liu X: Screening of the metastasis-associated genes by gene chip in high metastatic human ovarian cancer cell lines. J Genet Genomics; 2007 Jul;34(7):581-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of the metastasis-associated genes by gene chip in high metastatic human ovarian cancer cell lines.
  • Affymetrix U133A oligonucleotide microarrays were used to study the differences of gene expressions between high (H) metastatic ovarian cancer cell line, HO-8910PM, and normal ovarian tissues (C), bioinformatics was used to identify their chromosomal localizations.
  • Therefore it was concluded that differentially expressed genes in high metastatic ovarian cancer cell were supposed to be randomly distributed across the genome, but the majority were found on chromosomes 1, 2, 12, 11, 17, and X.
  • Abnormality in four groups of genes, including in enzyme and its regulator, nucleic acid binding, signal transduction and protein binding associated genes, might play important roles in ovarian cancer metastasis.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Neoplasm Metastasis / genetics. Oligonucleotide Array Sequence Analysis. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Chromosomes, Human / genetics. Female. Humans. Multigene Family. Nucleic Acid Hybridization. Ovary / cytology. Ovary / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643943.001).
  • [ISSN] 1673-8527
  • [Journal-full-title] Journal of genetics and genomics = Yi chuan xue bao
  • [ISO-abbreviation] J Genet Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Karam AK, Stempel M, Barakat RR, Morrow M, Gemignani ML: Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass. Gynecol Oncol; 2009 Mar;112(3):490-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
  • OBJECTIVE: A breast and/or axillary mass in a patient with epithelial ovarian cancer (EOC) may be due to an EOC breast metastasis or a second primary breast cancer.
  • METHODS: Between 1/90 and 10/07, 29 women with epithelial EOC presented with a breast or axillary mass, including 10 patients with EOC metastatic to the breast and/or axilla and 19 patients with a second primary breast cancer following their original EOC diagnosis.
  • RESULTS: The mean EOC disease-free survival (DFS) was 14.9 mo versus 77.4 mo (P<0.001) for patients with recurrent epithelial ovarian cancer metastatic to the breast and/or axilla and patients with a second primary breast cancer, respectively.
  • Similarly, the mean interval between diagnosis of EOC and the breast and/or axillary event was 31.2 mo versus 70.7 mo for those patients who had metastatic recurrent EOC and those patients with breast cancer (P=0.02).
  • Patients with a second primary breast cancer were more likely to be diagnosed on mammogram and have a family history of breast and ovarian carcinoma than patients with metastatic EOC to the breast and/or axilla (14/19 [73.7%] versus 2/9 [22.8%], P=0.02; and 12/18 [66.7%] versus 2/10 [20%], P=0.05, respectively).
  • Median overall survival for patients with EOC metastasis was 26 mo but was not yet reached for those patients with a second primary breast cancer.
  • On univariate analysis, an ovarian cancer DFS of 12 mo or more and the performance of breast/axillary surgery were associated with a significantly longer overall survival (P=0.01 and 0.02, respectively), whereas an elevated CA125 level at the time of the breast/axilla event and the presence of EOC metastases to the breast and axilla were significant negative predictors of survival (P=0.01 and 0.05, respectively).
  • CONCLUSION: The interval between EOC diagnosis and the breast and/or axilla event, an elevated CA125 level, and a family history of breast and/or ovarian cancer may help differentiate patients with metastatic EOC to the breast and/or axilla from those patients with a second primary breast cancer.
  • The presence of a metastatic EOC portends a poor prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / secondary. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease-Free Survival. Epithelial Cells / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies


77. Evans CL, Rizvi I, Hasan T, de Boer JF: In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging. Opt Express; 2009 May 25;17(11):8892-906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging.
  • In vitro three-dimensional models for metastatic ovarian cancer have been useful for recapitulating the human disease.
  • The development of a time-lapse OCT system, capable of automated, multidimensional acquisition, further provided insights into the growth and chemotherapeutic response of ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):266-76 [12001988.001]
  • [Cites] Arch Ophthalmol. 2005 Dec;123(12):1715-20 [16344444.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1516-24 [16234565.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Opt Lett. 2005 Apr 1;30(7):747-9 [15832926.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):C1109-23 [9357753.001]
  • [Cites] Cytometry. 1997 Jan 1;27(1):1-20 [9000580.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):041205 [17867794.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):242-7 [17163781.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):467-74 [10744824.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] J Am Coll Cardiol. 2002 Feb 20;39(4):604-9 [11849858.001]
  • [Cites] Opt Lett. 2006 Apr 15;31(8):1079-81 [16625909.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Phys Rev Lett. 2004 Mar 26;92(12):123905 [15089675.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 2):1972-9 [3512077.001]
  • [Cites] Science. 1990 Apr 6;248(4951):73-6 [2321027.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):588-95 [8938139.001]
  • (PMID = 19466138.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R01 RR019768; United States / NIAMS NIH HHS / AR / R01 AR040352; United States / NIAMS NIH HHS / AR / AR040352-09; United States / NIAMS NIH HHS / AR / R01 AR040352-09; United States / NCRR NIH HHS / RR / RR019768-01; United States / NCRR NIH HHS / RR / R01 RR019768-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS180857; NLM/ PMC2836890
  •  go-up   go-down


78. Oremek G, Sauer-Eppel H, Klepzig M: Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res; 2007 Jul-Aug;27(4A):1961-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer.
  • Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated.
  • These markers are abnormally raised in the blood of patients with metastatic bone disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Collagen Type I / blood. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649805.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Collagen Type I; 0 / Mucin-1
  •  go-up   go-down


79. Batashki I, Amaliev I, Markova D, Amaliev G, Milchev N: [Ovarian cancer with metastatic lesion in the vagina (foetus papiraceus)]. Akush Ginekol (Sofiia); 2009;48(3):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer with metastatic lesion in the vagina (foetus papiraceus)].
  • Ovarian cancer spreads primarily by intraperitoneal implantation of exfoliated cancer cells, by lymphatic dissemination, and by haematogenous spread.
  • We present a case of ovarian cancer with initial clinical manifestation-lesion of the vagina.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / secondary


80. Kim MJ: The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci; 2005 Aug;20(4):643-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
  • Distinguishing primary ovarian carcinoma from metastatic carcinoma to the ovary is often difficult by histologic examination alone.
  • Recently an immunohistochemical marker CDX-2 was found to be of considerable diagnostic value in establishing the gastrointestinal origin of metastatic tumors.
  • Paraffin-embedded tissue sections from 57 primary ovarian tumors and 40 metastatic tumors to the ovary were immunostained for CDX-2, and results were compared to the ancillary immunohistochemical results for CK7/CK20, CEA, CA125, and her-2/neu.
  • CDX-2 immunoreactivity was observed in most of metastatic carcinomas with colorectal (91%) and appendiceal (100%) origin, however CDX-2 was negative in all primary ovarian carcinomas, except for the mucinous subtype.
  • Almost all primary ovarian carcinomas including the mucinous subtype showed diffuse and strong immunoexpression for CK7.
  • CEA and CA125 were mainly found in metastatic and primary ovarian carcinoma, respectively.
  • Her-2/neu overexpression was only noted in a small proportion of primary and metastatic ovarian carcinomas.
  • These results suggest that CDX-2 is very useful immunohistochemical marker for distinguishing metastatic colorectal carcinoma to the ovary from primary ovarian carcinoma, including the mucinous subtype.
  • [MeSH-major] Homeodomain Proteins / analysis. Ovarian Neoplasms / pathology. Tissue Array Analysis / methods. Trans-Activators / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):672-7 [10872659.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Cancer Lett. 2002 Feb 8;176(1):47-55 [11790453.001]
  • [Cites] J Gastroenterol. 2002;37(2):94-100 [11871772.001]
  • [Cites] Int J Oncol. 2002 Oct;21(4):769-74 [12239615.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):141-9 [12548159.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):28-31 [12631216.001]
  • [Cites] Arch Pathol Lab Med. 2003 Dec;127(12):1586-90 [14632574.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):52-7 [14668551.001]
  • [Cites] Adv Anat Pathol. 2004 Mar;11(2):101-5 [15090846.001]
  • [Cites] Virchows Arch. 2004 Jul;445(1):63-7 [15175880.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):751-8 [1595595.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):219-23 [7506222.001]
  • [Cites] Hum Pathol. 1994 Jul;25(7):666-70 [8026826.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):852-5 [7543441.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):619-25 [8552090.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):426-9 [8729984.001]
  • [Cites] J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105 [8796816.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):283-90 [10474521.001]
  • [Cites] J Clin Pathol. 2000 May;53(5):327-34 [10889812.001]
  • (PMID = 16100458.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2782162
  •  go-up   go-down


81. Sterman DH, Gillespie CT, Carroll RG, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, June CH, Albelda SM, Vonderheide RH: Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol; 2006 Nov;3(11):633-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon beta adenoviral gene therapy in a patient with ovarian cancer.
  • Background A 47-year-old woman with a history of ovarian cancer and a 6-year disease-free remission presented with dyspnea and increased abdominal girth.
  • The patient was found to have ascites and a large left pleural effusion, both of which contained malignant cells consistent with recurrent ovarian cancer.
  • Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion.
  • [MeSH-major] Genetic Therapy. Interferon-beta / genetics. Interferon-beta / therapeutic use. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080181.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 66726
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta
  •  go-up   go-down


82. Tinelli A, Vergara D, Martignago R, Leo G, Malvasi A, Tinelli R, Marsigliante S, Maffia M, Lorusso V: Ovarian cancer biomarkers: a focus on genomic and proteomic findings. Curr Genomics; 2007 Aug;8(5):335-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer biomarkers: a focus on genomic and proteomic findings.
  • Among the gynaecological malignancies, ovarian cancer is one of the neoplastic forms with the poorest prognosis and with the bad overall and disease-free survival rates than other gynaecological cancers; several studies, analyzing clinical data and pathological features on ovarian cancers, have focused on the identification of both diagnostic and prognostic markers for applications in clinical practice.
  • High-throughput technologies have accelerated the process of biomarker discovery, but their validity should be still demonstrated by extensive researches on sensibility and sensitivity of ovarian cancer novel biomarkers, determining whether gene profiling and proteomics could help differentiate between patients with metastatic ovarian cancer and primary ovarian carcinomas, and their potential impact on management.Therefore, considerable interest lies in identifying molecular prognostic biomarkers and protein indicators to guide treatment decisions and clinical follow up; the current state of knowledge about the potential clinical value of gene expression profiling in ovarian cancer is discussed, focusing on three main areas: distinguishing normal ovarian tissue from ovarian tumors, identifying different subtypes of ovarian cancer and identifying cancer likely to be responsive to therapy.In this elaborate we discuss the use of novel molecules, discovered by proteomics and genomics approaches, as potential protein biomarkers in the management of ovarian cancer, to improve the anticancer therapy for malignant ovarian tumors and to monitor the clinical follow up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Sep 15;107(6):1407-18 [16902988.001]
  • [Cites] EMBO Rep. 2006 Jun;7(6):599-604 [16741504.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1707-14 [16551853.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Clin Chem. 1999 May;45(5):651-8 [10222351.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):315-25 [9633843.001]
  • [Cites] Genomics. 1997 Mar 1;40(2):371-4 [9119409.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2011-5 [8634993.001]
  • [Cites] Ann Med. 1995 Feb;27(1):73-8 [7742004.001]
  • [Cites] Clin Chim Acta. 1994 Jun;227(1-2):87-96 [7525119.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1030-4 [8490497.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Sep;84(18):6379-83 [2819873.001]
  • [Cites] BMJ. 1989 Dec 2;299(6712):1363-7 [2513964.001]
  • [Cites] Am J Obstet Gynecol. 1986 Jul;155(1):50-5 [3460340.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):761-8 [14984938.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1067-78 [14578472.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):725-31 [17610223.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2509-17 [17547437.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):1993-2002 [17620429.001]
  • [Cites] Ann Oncol. 2007 May;18(5):881-5 [17301071.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):103-8 [17479670.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(2):83-8 [17479666.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1440-50 [17315909.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5 [17403417.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1670-9 [17308108.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):772-80 [17269733.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4943-8 [17214367.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):332-40 [17154180.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):10-5 [17197890.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):382-9 [12915129.001]
  • [Cites] Nature. 2002 Nov 7;420(6911):19 [12422186.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):47-59 [11960694.001]
  • [Cites] Br J Nutr. 2002 Jan;87 Suppl 1:S23-9 [11895152.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):282-5 [11553857.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8018-23 [11416160.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):4965-8 [11326648.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1511-9 [16944535.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9338-43 [16361633.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9415-25 [16230405.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):618-23 [16014115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1729-36 [15841084.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2485-90 [10499623.001]
  • [Cites] Nat Med. 1999 Aug;5(8):938-42 [10426319.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):849-51 [10216504.001]
  • (PMID = 19384429.001).
  • [ISSN] 1389-2029
  • [Journal-full-title] Current genomics
  • [ISO-abbreviation] Curr. Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2652404
  • [Keywords] NOTNLM ; Ovarian cancer / biomarkers / genomics / management. / proteomics
  •  go-up   go-down


83. Raki M, Hakkarainen T, Bauerschmitz GJ, Särkioja M, Desmond RA, Kanerva A, Hemminki A: Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther; 2007 Oct;14(19):1380-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ad5/3-Delta24-TK-GFP killed ovarian cancer cells effectively, which correlated with GFP expression.
  • In murine models of metastatic ovarian cancer, Ad5/3-Delta24-TK-GFP improved antitumor efficacy over the respective replication-deficient virus with GCV.
  • [MeSH-major] Genetic Therapy / methods. Oncolytic Virotherapy / methods. Ovarian Neoplasms / therapy. Protein-Tyrosine Kinases / genetics. Simplexvirus / enzymology
  • [MeSH-minor] Animals. Antiviral Agents / metabolism. Antiviral Agents / therapeutic use. Carcinoma / secondary. Carcinoma / therapy. Cell Line, Tumor. Female. Ganciclovir / metabolism. Ganciclovir / therapeutic use. Gene Expression. Genetic Engineering. Green Fluorescent Proteins / genetics. Humans. Mice. Mice, Nude. Mice, SCID. Models, Animal. Neoplasm Transplantation. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Virus Replication

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611584.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


84. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res; 2009 Sep 1;69(17):7121-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.
  • An early event in the metastasis of epithelial ovarian carcinoma is shedding of cells from the primary tumor into the peritoneal cavity followed by diffuse i.p. seeding of secondary lesions.
  • Anchorage-independent metastatic cells are present as both single cells and multicellular aggregates (MCA), the latter of which adhere to and disaggregate on human mesothelial cell monolayers, subsequently forming invasive foci.
  • Although this unique metastatic mechanism presents a distinct set of therapeutic challenges, factors that regulate MCA formation and dissemination have not been extensively evaluated.
  • Proteolytic activity is important at multiple stages in i.p. metastasis, catalyzing migration through the mesothelial monolayer and invasion of the collagen-rich submesothelial matrix to anchor secondary lesions, and acquisition of membrane type 1 matrix metalloproteinase (MT1-MMP; MMP-14) expression promotes a collagen-invasive phenotype in ovarian carcinoma.
  • MT1-MMP is regulated posttranslationally through multiple mechanisms including phosphorylation of its cytoplasmic tail, and the current data using ovarian cancer cells expressing wild-type, phosphomimetic (T567E-MT1-MMP), and phosphodefective (T567A-MT1-MMP) MT1-MMP show that MT1-MMP promotes MCA formation.
  • Analysis of human ovarian tumors shows elevated MT1-MMP in metastases relative to paired primary tumors.
  • These data suggest that MT1-MMP activity may be key to ovarian carcinoma metastatic success by promoting both formation and dissemination of MCAs.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Jun 12;149(6):1309-23 [10851027.001]
  • [Cites] J Biol Chem. 2009 Jul 24;284(30):19791-9 [19458085.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4837-41 [11406560.001]
  • [Cites] J Soc Gynecol Investig. 2001 Sep-Oct;8(5):299-304 [11677151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13693-8 [11698655.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1345-56 [11756481.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):632-8 [12134161.001]
  • [Cites] Biotechnol Bioeng. 2003 Jul 20;83(2):173-80 [12768623.001]
  • [Cites] Cell. 2003 Jul 11;114(1):33-45 [12859896.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):170-81 [15047232.001]
  • [Cites] Am J Obstet Gynecol. 1974 Aug 1;119(7):991-4 [4276313.001]
  • [Cites] J Pathol. 1983 Mar;139(3):337-47 [6834177.001]
  • [Cites] Exp Cell Res. 1985 Oct;160(2):499-513 [3899694.001]
  • [Cites] Clin Exp Metastasis. 1987 Apr-Jun;5(2):181-97 [3297449.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):5028-32 [8402695.001]
  • [Cites] Lab Invest. 1994 Mar;70(3):333-8 [8145527.001]
  • [Cites] Curr Opin Genet Dev. 1994 Feb;4(1):82-9 [8193545.001]
  • [Cites] Nature. 1994 Jul 7;370(6484):61-5 [8015608.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17119-23 [8663332.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2446-51 [8999957.001]
  • [Cites] Eur J Biochem. 1997 Dec 15;250(3):751-7 [9461298.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1635-41 [10197640.001]
  • [Cites] Cell. 1999 Oct 1;99(1):81-92 [10520996.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):316-9 [16240401.001]
  • [Cites] Semin Reprod Med. 2006 Sep;24(4):270-82 [16944424.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4924-31 [17158885.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2030-9 [17332331.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1463-72 [17546601.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):358-67 [17609667.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):872-85 [17455221.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):24-33 [17702616.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):385-94 [18036641.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):643-55 [18398687.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1655-64 [18621744.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7247-9 [18794108.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):319-24 [18976802.001]
  • [Cites] Mol Cancer Res. 2009 Jun;7(6):809-20 [19509114.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1279-88 [11290546.001]
  • (PMID = 19706774.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109545-04; United States / NCI NIH HHS / CA / CA86984; United States / NCI NIH HHS / CA / R01 CA086984-09; United States / NCI NIH HHS / CA / CA086984-09S1; United States / NCI NIH HHS / CA / R01 CA086984; United States / NCI NIH HHS / CA / R01 CA086984-08S1; United States / NCI NIH HHS / CA / CA86984-S1; United States / NCI NIH HHS / CA / CA109545; United States / NCI NIH HHS / CA / R01 CA109545-03; United States / NCI NIH HHS / CA / CA086984-08; United States / NCI NIH HHS / CA / CA109545-03; United States / NCI NIH HHS / CA / R01 CA109545; United States / NCI NIH HHS / CA / R01 CA086984-08; United States / NCI NIH HHS / CA / R01 CA086984-09S1; United States / NCI NIH HHS / CA / CA086984-08S1; United States / NCI NIH HHS / CA / CA086984-09; United States / NCI NIH HHS / CA / CA109545-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS128017; NLM/ PMC2737080
  •  go-up   go-down


85. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma].
  • OBJECTIVE: To detect the expression of the protein of TGF-beta1 and E-cadherin in the primary and metastatic lesions of ovarian carcinoma and explore the mechanism of the metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • A significant correlation was found between the expressions of the TGF-beta1 and E-cadherin in the primary carcinoma (Kappa value of -0.32, P=0.01).
  • CONCLUSION: TGF-beta1 and E-cadherin are closely associated with the metastasis of ovarian carcinoma and might be potential targets for controlling the metastasis of ovarian carcinoma.
  • [MeSH-major] Cadherins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


86. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW, Finkelstein D, Hasan T: Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res; 2010 Nov 15;70(22):9319-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer.
  • Metastatic ovarian cancer (OvCa) frequently recurs due to chemoresistance, highlighting the need for nonoverlapping combination therapies that mechanistically synergize to eradicate residual disease.
  • Photodynamic therapy (PDT), a photochemistry-based cytotoxic modality, sensitizes ovarian tumors to platinum agents and biologics and has shown clinical promise against ovarian carcinomatosis.
  • We introduce a three-dimensional (3D) model representing adherent ovarian micrometastases and high-throughput quantitative imaging methods to rapidly screen the order-dependent effects of combining benzoporphyrin-derivative (BPD) monoacid A-based PDT with low-dose carboplatin.
  • 3D ovarian micronodules grown on Matrigel were subjected to BPD-PDT either before or after carboplatin treatment.
  • Carboplatin alone did not eradicate ovarian micrometastases at a dose of 400 mg/m2, leaving surviving cores that were nonsensitive or impermeable to chemotherapy.
  • This approach combining biological modeling with high-content imaging provides a platform to rapidly screen therapeutic strategies for a broad array of metastatic tumors.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AACR.
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1075-82 [8640764.001]
  • [Cites] J Biomed Opt. 2010 Sep-Oct;15(5):051603 [21054077.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Exp Cell Res. 1998 Dec 15;245(2):350-9 [9851876.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):95-100 [10408699.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1557-63 [10491432.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2885-9 [16080542.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1516-24 [16234565.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Mar;7(3):211-24 [16496023.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2517-25 [16638861.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):516-21 [16607618.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):583-92 [16862189.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1463-72 [17546601.001]
  • [Cites] Photochem Photobiol. 2007 Sep-Oct;83(5):1024-8 [17880495.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:29-32 [18336396.001]
  • [Cites] Drugs. 2008;68(6):771-89 [18416585.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31 [18495520.001]
  • [Cites] Curr Med Chem. 2008;15(17):1655-73 [18673216.001]
  • [Cites] Mol Pharm. 2008 Sep-Oct;5(5):696-709 [18729468.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Opt Express. 2009 May 25;17(11):8892-906 [19466138.001]
  • [Cites] Gynecol Oncol. 2009 Jul;114(1):26-31 [19395008.001]
  • [Cites] J Vis Exp. 2009;(34). pii: 1692. doi: 10.3791/1692 [20019656.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):65-71 [11206227.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):31-46 [11489481.001]
  • [Cites] Photochem Photobiol. 2001 Aug;74(2):318-22 [11547571.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3904-11 [11751481.001]
  • [Cites] Can J Gastroenterol. 2002 Jun;16(6):393-6 [12096303.001]
  • [Cites] Mol Cell Endocrinol. 2003 Apr 28;202(1-2):89-96 [12770736.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4261-7 [14666636.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):318-24 [1998474.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9064-8 [1384042.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):445-57 [8436523.001]
  • [Cites] Photochem Photobiol. 1994 Mar;59(3):328-35 [8016212.001]
  • [Cites] Oncology. 2009;77(6):400-10 [20130423.001]
  • [Cites] Nat Rev Cancer. 2010 Apr;10(4):241-53 [20300105.001]
  • [Cites] Gynecol Oncol. 2010 May;117(2):152-8 [20056266.001]
  • [Cites] Chem Rev. 2010 May 12;110(5):2795-838 [20353192.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Mar;104(3):376-8 [9091020.001]
  • (PMID = 21062986.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32CA138153; United States / NCI NIH HHS / CA / R01CA146337; United States / NCI NIH HHS / CA / F32 CA138153; United States / NCI NIH HHS / CA / CA119388-05; United States / NCI NIH HHS / CA / R01 CA119388-05; United States / NIAMS NIH HHS / AR / R01 AR040352; United States / NCI NIH HHS / CA / R01 CA119388; United States / CCR NIH HHS / RC / CA146337-01; United States / NCI NIH HHS / CA / RC1 CA146337-01; United States / NIAMS NIH HHS / AR / R01 AR040352-11; United States / NIAMS NIH HHS / AR / R01AR040532; United States / NCI NIH HHS / CA / R01CA119388; United States / NCI NIH HHS / CA / RC1 CA146337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Fibronectins; 0 / Porphyrins; 129497-78-5 / verteporfin; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS242704; NLM/ PMC3057933
  •  go-up   go-down


87. Avitia S, Hamilton JS, Osborne RF: Metastatic ovarian cancer in the head and neck. Ear Nose Throat J; 2008 Jun;87(6):318
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ovarian cancer in the head and neck.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Ovarian Neoplasms / surgery


88. Bagnato A, Rosanò L: Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs; 2007;185(1-3):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
  • In ovarian carcinoma, acquisition of invasiveness is accompanied by the loss of the epithelial features and the gain of a mesenchymal phenotype, a process known as epithelial-mesenchymal transition (EMT).
  • The endothelin A receptor (ET(A)R)/endothelin-1 (ET-1) axis is overexpressed in primary and metastatic ovarian carcinoma.
  • In this tumor type, the ET-1/ET(A)R axis has a critical role in ovarian carcinoma progression by inducing proliferation, survival, neoangiogenesis, loss of intercellular communication and invasion.
  • Recently, we demonstrated that the ET-1/ET(A)R autocrine pathway drives EMT in ovarian tumor cells by inducing an invasive phenotype through downregulation of E-cadherin, increased levels of beta-catenin, Snail and other mesenchymal markers, and suppression of E-cadherin promoter activity.
  • In ovarian carcinoma xenografts, the specific ET(A)R antagonist ABT-627 suppresses EMT determinants and tumor growth.
  • In human ovarian cancers, ET(A)R expression is associated with E-cadherin downregulation, N-cadherin expression and tumor grade.
  • In conclusion, our findings demonstrate that ET(A)R activation by ET-1 is a key mechanism of the complex signaling network that promotes EMT as well as ovarian cancer cell invasion.
  • The small molecule ET(A)R antagonist achieves concomitant suppression of tumor growth and EMT effectors, providing a new opportunity for therapeutic intervention in which targeting ILK pathway and the related Snail and beta-catenin signaling cascade via ET(A)R blockade may be advantageous in the treatment of ovarian cancer.
  • [MeSH-major] Endothelin-1 / physiology. Epithelium / pathology. Mesoderm / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Animals. Disease Progression. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Models, Biological. Neoplasm Invasiveness. Receptor, Endothelin A / genetics. Receptor, Endothelin A / metabolism


89. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR Jr: Predicting risk of malignancy in adnexal masses. Obstet Gynecol; 2010 Apr;115(4):687-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariable classification and regression tree analysis were used to identify a group of patients at high risk of ovarian malignancy.
  • RESULTS: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors.
  • Multivariable classification and regression tree analysis defined women at high risk of ovarian malignancy as those with an adnexal mass having complex or solid morphology and a serum CA 125 value greater than 35 units/mL.
  • This definition had a positive predictive value of 84.7% and a negative predictive value of 92.4% and correctly identified 77.3% of patients with stage I and stage II ovarian cancer and 98.6% of patients with stage III and stage IV ovarian cancer.
  • CONCLUSION: Patients with solid or complex ovarian tumors and an elevated serum CA 125 level (greater than 35 units/mL) are at high risk of ovarian malignancy.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2010 Apr;115(4):680-1 [20308824.001]
  • (PMID = 20308826.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


90. Brown JV 3rd, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP: Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain. Gynecol Oncol; 2005 Jun;97(3):858-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain.
  • BACKGROUND: Central nervous system (CNS) metastases from an ovarian malignancy are uncommon.
  • CASES: We present three ovarian cancer patients who developed metastatic disease to the brain.
  • CONCLUSION: Local control of ovarian cancer metastatic to the brain can be achieved in some patients with GKRS.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Ovarian Neoplasms / pathology. Radiosurgery


91. Li F, Gurudu SR, De Petris G, Sharma VK, Shiff AD, Heigh RI, Fleischer DE, Post J, Erickson P, Leighton JA: Retention of the capsule endoscope: a single-center experience of 1000 capsule endoscopy procedures. Gastrointest Endosc; 2008 Jul;68(1):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic ovarian cancer with invasion of the ileum was the cause of retention in another patient.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513723.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Mirkovic I, Mlodzik M: Cooperative activities of drosophila DE-cadherin and DN-cadherin regulate the cell motility process of ommatidial rotation. Development; 2006 Sep;133(17):3283-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cooperative activities of drosophila DE-cadherin and DN-cadherin regulate the cell motility process of ommatidial rotation.
  • Here, we demonstrate that the Drosophila DE- and DN-cadherins have opposing effects on rotation.
  • DE-cadherin promotes rotation, as DE-cad mutant ommatidia rotate less than wild type or not at all.
  • The opposing effects of DE- and DN-cadherins result in a coordinated cellular movement, enabling ommatidia of the same stage to rotate simultaneously.
  • Thus, DE- and DN-cadherins integrate inputs from at least two signaling pathways, resulting in a coordinated cell movement.
  • A similar input into mammalian E- and N-cadherins might function in the progression of diseases such as metastatic ovarian cancer.


93. Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC: Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer; 2005 Sep 19;93(6):647-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.
  • Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer.
  • We conducted a nonrandomised phase II evaluation of combination endocrine therapy with tamoxifen and goserelin in patients with advanced ovarian cancer that had recurred following chemotherapy.
  • Inhibin is unlikely to be a useful surrogate marker for response in locally advanced or metastatic ovarian cancer.
  • Combination endocrine therapy with tamoxifen and goserelin is an active regimen in platinum-resistant ovarian cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3627-30 [10629663.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):194-202 [10926802.001]
  • [Cites] Am J Reprod Immunol. 2000 Aug;44(2):104-13 [10994638.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4280-6 [11095468.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(1):CD001034 [11279703.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Gynecol Oncol. 2002 Feb;84(2):201-9 [11812075.001]
  • [Cites] Mol Cell Endocrinol. 2002 May 31;191(1):97-103 [12044923.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):297-301 [12217751.001]
  • [Cites] Anticancer Res. 1988 May-Jun;8(3):417-34 [3291746.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):115-8 [2491882.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567-72 [3208800.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Feb;25(2):215-21 [2649375.001]
  • [Cites] BMJ. 1991 Feb 2;302(6771):259-62 [1998789.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):269-71 [2070324.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1401-5 [8636341.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):64-9 [8995549.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):199-206 [9699874.001]
  • [Cites] Clin Chem. 1999 May;45(5):651-8 [10222351.001]
  • [Cites] Recent Results Cancer Res. 2000;153:83-94 [10626291.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):621-3 [1314071.001]
  • [Cites] Gynecol Endocrinol. 1992 Dec;6(4):271-4 [1492583.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1957-68 [7691999.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1539-42 [8413476.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):80-6 [8020844.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Jun;40(6):717-23 [8033361.001]
  • [Cites] Eur J Cancer. 1994;30A(5):682-6 [8080688.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2555-61 [7522953.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):285-9 [7959297.001]
  • [Cites] Hum Reprod. 1994 Jul;9(7):1364-79 [7962452.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2926-32 [7559876.001]
  • [Cites] Oncologist. 2000;5(1):26-35 [10706647.001]
  • (PMID = 16222310.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 0F65R8P09N / Goserelin
  • [Other-IDs] NLM/ PMC2361624
  •  go-up   go-down


94. Fujiwara M, Taube J, Sharma M, McCalmont TH, Kim J: PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. J Cutan Pathol; 2010 Sep;37(9):938-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
  • BACKGROUND: The distinction of metastatic ovarian carcinoma from other metastatic carcinomas and primary adnexal lesions in the skin is often difficult.
  • PAX8 is a transcription factor that plays a critical role in development of the Müllerian system and has been shown to be a useful discriminatory marker between ovarian and breast carcinomas.
  • Identification of ovarian cutaneous metastases may be of benefit in patients with familial breast-ovarian carcinoma syndrome.
  • METHODS: PAX8 immunohistochemical analysis was performed on 24 cases of metastatic adenocarcinomas to the skin and compared with 7 cases of primary adnexal lesions and also compared with p63 immunohistochemical staining results.
  • Patients with metastatic adenocarcinomas had clinically documented primary malignancies, and patients with primary adnexal carcinomas had no known history of another adenocarcinoma.
  • RESULTS: Cutaneous ovarian and renal cell carcinoma metastases (2/2 and 8/8, respectively) showed positive nuclear expression of PAX8.
  • The p63 expression profile supported the distinction between adnexal and metastatic adenocarcinomas.
  • CONCLUSIONS: Although cutaneous ovarian metastasis is a rare phenomenon, the prognosis is extremely poor.
  • PAX8 expression is a useful marker that effectively discriminated metastatic ovarian carcinomas from metastatic breast carcinomas and primary adnexal tumors.
  • [MeSH-major] Neoplasms, Adnexal and Skin Appendage / diagnosis. Ovarian Neoplasms / diagnosis. Paired Box Transcription Factors / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492080.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


95. Le T, Hopkins L, Fung Kee Fung M: Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):811-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy.
  • To study the immediate and long-term effects of chemotherapy on quality of life (QoL) of advanced ovarian cancer patients.
  • All consecutive patients undergoing chemotherapy for metastatic ovarian cancer and those presenting for follow-up post chemotherapy were recruited.
  • Participants were asked to fill out a short QoL questionnaire (Functional Assessment Cancer Therapy-Ovarian) during each clinic visit.
  • Patients on chemotherapy for recurrent disease had a significantly worsened overall, emotional, and ovarian cancer-specific concerns QoL scores compared to those receiving first-line chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / psychology. Quality of Life. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174229.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol; 2007 Jun;35(6):370-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
  • The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters.
  • The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
  • Metastatic OACs showed positive immunoreactivity to WT1 in 19/20 (95%) cases, CA125 in 20/20 (100%), and all showed negative reaction for both mCEA (0/20, 0%) and TTF1 (0/20, 0%).
  • Our results demonstrate that the WT1 stain is specific for metastatic carcinoma of ovarian primary, showing a high sensitivity.
  • A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary.
  • Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
  • [MeSH-minor] Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497661.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / WT1 Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


97. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P: A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):6106-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
  • PURPOSE: A phase I study was conducted to assess the safety of adoptive immunotherapy using gene-modified autologous T cells for the treatment of metastatic ovarian cancer.
  • EXPERIMENTAL DESIGN: T cells with reactivity against the ovarian cancer-associated antigen alpha-folate receptor (FR) were generated by genetic modification of autologous T cells with a chimeric gene incorporating an anti-FR single-chain antibody linked to the signaling domain of the Fc receptor gamma chain.
  • This report is the first to document the use of genetically redirected T cells for the treatment of ovarian cancer.
  • [MeSH-major] Immunotherapy, Adoptive / adverse effects. Lymphocyte Transfusion / adverse effects. Ovarian Neoplasms / immunology. T-Lymphocytes / transplantation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2000 Nov 20;11(17):2377-87 [11096442.001]
  • [Cites] Prostate. 2004 Sep 15;61(1):12-25 [15287090.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1085-91 [16251873.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):9080-8 [16204083.001]
  • [Cites] Oncology. 2005;68(2-3):154-61 [16020953.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9160-6 [15604287.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1774-81 [15599402.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):62-8 [9988234.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):991-6 [9500461.001]
  • [Cites] Cancer Treat Res. 1996;82:115-46 [8849947.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):406-12 [8621218.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3369-73 [7614473.001]
  • [Cites] Eur J Cancer. 1994;30A(3):363-9 [8204360.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1731-7 [8156501.001]
  • [Cites] J Exp Med. 1993 Jul 1;178(1):361-6 [8315392.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6125-32 [1840502.001]
  • [Cites] Br J Cancer Suppl. 1990 Jul;10:15-7 [2383475.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1709-17 [2810387.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):297-303 [2434438.001]
  • [Cites] Science. 1986 Sep 19;233(4770):1318-21 [3489291.001]
  • [Cites] Cancer Res. 1986 Jun;46(6):3118-24 [3516392.001]
  • [Cites] Cancer Res. 1985 Oct;45(10):4970-9 [3861241.001]
  • [Cites] J Immunother. 2000 Nov-Dec;23(6):661-8 [11186154.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3155-63 [12384413.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5780-6 [12421958.001]
  • [Cites] Nat Biotechnol. 2002 Dec;20(12):1221-7 [12415288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1232-7 [12547911.001]
  • [Cites] Cancer Cell. 2003 May;3(5):431-7 [12781360.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):5-18 [15233937.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):54-60 [15262119.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):928-40 [16322746.001]
  • (PMID = 17062687.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC003811-32
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS35281; NLM/ PMC2154351
  •  go-up   go-down


98. Bristow RE, Palis BE, Chi DS, Cliby WA: The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol; 2010 Sep;118(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.
  • OBJECTIVE: To examine the effect of hospital procedure volume and other prognostic variables on overall survival outcome and likelihood of receiving standard recommended care among patients with advanced-stage epithelial ovarian cancer.
  • METHODS: The National Cancer Data Base (NCDB) was searched for patients undergoing primary treatment for FIGO Stage IIIC/IV epithelial ovarian cancer from 1996 to 2005.
  • Cox proportional hazards modeling was used to determine the impact on overall survival of hospital surgical volume adjusted for treatment, FIGO/AJCC stage, ethnicity, age, payer status, household income, and tumor grade.
  • CONCLUSIONS: Hospital ovarian cancer surgical volume >or=21 cases/year is associated with a higher likelihood of patients with Stage IIIC/IV epithelial ovarian cancer receiving standard treatment (surgery followed by adjuvant chemotherapy).
  • [MeSH-major] Gynecologic Surgical Procedures / statistics & numerical data. Hospitals / statistics & numerical data. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / surgery


99. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA: LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol; 2009 Jan;112(1):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LPA receptor 2 mediates LPA-induced endometrial cancer invasion.
  • OBJECTIVE: We have previously shown that lysophosphatidic acid (LPA) promotes the ovarian cancer metastatic cascade.
  • In this study, we evaluated the role of LPA on endometrial cancer invasion.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019417.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA125227-01; United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / R21 CA125227-01; United States / NCI NIH HHS / CA / U01 CA85133
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


100. Li QL, Bu N, Yu YC, Hua W, Xin XY: Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Med Oncol; 2008;2:461-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment.
  • We hypothesized that the exosomes released from metastatic ovarian carcinoma were able to present tumor specific antigen to dendritic cells derived from unrelated umbilical cord blood, then could stimulate resting T cells to differentiate and induce effective cytotoxicity.
  • STUDY DESIGN: Exosomes were isolated by ultracentrifugation of malignant ascites from ovarian cancer patients (n = 10).
  • CONCLUSIONS: These results suggested that tumor-specific antigens present on exosomes can be presented by DCs derived from unrelated umbilical cord blood to induce tumor specific cytotoxicity and this may represent as a novel immunotherapy for ovarian cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):305-11 [15655551.001]
  • [Cites] J Immunother. 2004 Jul-Aug;27(4):282-8 [15235389.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):8-14 [7557620.001]
  • [Cites] J Immunol Methods. 1994 Jan 3;167(1-2):145-60 [8308273.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1161-72 [8642258.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):695-706 [8760823.001]
  • [Cites] Methods. 1997 Jun;12(2):165-71 [9184380.001]
  • [Cites] N Engl J Med. 2000 Jun 22;342(25):1846-54 [10861319.001]
  • [Cites] J Cell Sci. 2000 Oct;113 Pt 19:3365-74 [10984428.001]
  • [Cites] Nat Med. 2001 Mar;7(3):297-303 [11231627.001]
  • [Cites] Transfus Clin Biol. 2001 Jun;8(3):146-54 [11499955.001]
  • [Cites] Nat Med. 1998 May;4(5):594-600 [9585234.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3235-41 [11907077.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(5):257-60 [12064362.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):295-305 [12147373.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):569-79 [12154376.001]
  • [Cites] Vaccine. 2002 Dec 19;20 Suppl 4:A28-31 [12477425.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10963-72 [12519789.001]
  • [Cites] Hum Immunol. 2003 Apr;64(4):427-39 [12651069.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jul;31(1):114-21 [14975938.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1807-15 [15111327.001]
  • [Cites] Vaccine. 2005 Mar 18;23(17-18):2374-8 [15755631.001]
  • [ExpressionOfConcernIn] Clin Med Insights Oncol. 2013 May 20;7:83 [23772178.001]
  • (PMID = 21892318.001).
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3161644
  • [Keywords] NOTNLM ; dendritic cells / exosome / immunotherapy / ovarian cancer / umbilical cord blood
  •  go-up   go-down






Advertisement